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Progestin metabolism in pregnant mares was investigated in five
experiments.The following progestins were analyzed: [5a-pregnane-
3,20-dione(5a-DHP),4-pregnene-3,20-dione(P4),3D-hydroxy-5-
pregnen-20-one (P5), 30-hydroxy-5a-pregnan-20-one (313-5P),20a-
hydroxy-5a-pregnan-3-one (20a-5P), 5-pregnene-3(3,2013-diol (P5-13f3),
5a-pregnane-313,200-diol (00-diol), and 5a-pregnane-313,20a-diol (I3a-
diol)1.Gas chromatography/mass spectrometry (GC/MS) techniques
allowed both definitive identification and quantification of steroids.
Sample preparationinvolvedtheadditionofinternalstandards,
extraction, and derivatization (methoxime/t-butyldimethylsilyl).
In Experiment 1, plasma samples from both fetal and maternal
vessels of six late-gestation mares indicated predominant progestins to
be:uterine vein (20a-5P mean=767.6+/-S.E.=217.8 ng/ml, pa-diol
202.2+1-44.5 ng/ml), maternal artery (20a-5P 533.2+/-201.8 ng/ml,
150.1+/-28.5 ng/ml), fetal vein (5a-DHP 216.4+/-24.4 ng/ml, P4
15.5+1-2.8 ng/ml), and fetal artery (P5 630.8+1-298.5 ng/ml, P5-130
131.4+/-51.8 ng/ml, 30-5P 117.9+/-17.0 ng/ml, 1313-diol 32.3+/-12.8
Redacted for privacyng /ml).The variation in levels of hormones in these vessels implies
metabolism of progestins occurs in severallocations.InExp.2,
deuterium (D4) P5 was infused into fetal arteries of two late-gestation
mares. D4-metabolites in plasma varied over time (P < .05), with Dq-
313-5P, D4-P4, and D4-5a-DHP higher (P < .05) in fetal vessels, and D4-
20a-5P and D4-ria-diol higher (P < .05) in maternal vessels. The primary
mare metabolite was D4-20a-5P, while the major fetal metabolite was
D4- 33 -5P.In Exp. 3, tissues from two late-gestation mares were
incubated with D4-PS. Highest production (P < .05) of D4-P4 occurred in
the placenta.D4-5a-DHP was greater (P < .05) in the endometrium,
placenta, and fetal ovary.D4-313-5P was higher (P < .05) in the fetal
ovary, adrenal and liver, and mare endometrium. Some D4-20a-5P was
produced by endometrium and fetal tissues. More D4-P5-(313 was
produced by fetal liver (P < .05).D4-11a-diol was produced primarily by
endometrium (P < .05).In Exp. 4, estrogens, progestins, an androgen, and
urokinase plasminogen activator were identified in nine embryos (d 14
to18).In Exp. 5, exogenous 5a-DHP and 313-5P were not as effective as
P4 in inhibiting estrus, ovulation, or equine luteinizing hormone.
The following metabolic model is suggested by this research.
Placenta and endometrium metabolize P5 to P4 and 5a -DHP.Both 30-
and 2013-hydroxylations occur in the fetus, while 20a-hydroxylations
occur in mare endometrium. Identification of steroids in early embryos
indicates elaborate enzyme systems early in gestation. As noted in Exp.
5, higher concentrations of 5a-DHP and 313-5P may be necessary to elicit
the same biological activity as P4. This area of research could enable
development of methods to determine feto-placental integrity in mares,
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INTRODUCTION
Over the past several decades, substantial technological advances
have been made which facilitateanalyzingtheendocrinologyof
pregnancy in most species.Immunoassays with specific antibodies to
thevarioushormones,coupledwithadvancedequipmentin
chromatography and ultrasound have allowed scientists and clinicians to
make significantcontributionstothisareaofresearch. The
interrelationships of the maternal, fetal, and placental units are of
functional importance to the success of the pregnancy, and thus are the
focus of intensive investigation. Without harmony within and between
these units, complications result which can culminate in a loss of
pregnancy which in turn cause both economic and sentimental losses to
the livestock producer.
Thus the focus of this research was on a critical time in the
livestock production scheme; the gestation of young.The equine was
investigated, which has some rather unique characteristics, yet still
serves as a good model for endocrine investigations.In a series of five
relatedstudies,someofthecomplexitiesofsteroidhormone
metabolism in the equine pregnancy were studied.Particular attention
was focussed on the numerous progestins of the equine fetus and
pregnantmare. Withexpandedknowledgeofthemetabolic
interrelationships of these progestins, such as their sources and
biological actions,it may allow the development of methods to
determine feto-placental integrity in the mare, and subsequently in
other species as well.2
REVIEW OF LITERATURE
PROGEST I N RESEARCH
1.Early Work on Progestlns
Nearly sixty years ago, on April11,1934, results from an
experimentinwhich4-pregnene-3,20-dione(progesterone)was
discovered, were presented to the German Society for Internal Medicine.
Of the scientistsinvolvedinthefourlaboratories which were
simultaneously working on the discovery, A, Butenandt and L. Rusicka
shared the Nobel prize for their contribution to the study of female sex
steroids. In a review article discussing this early work (Butenandt and
Westphal, 1974), it was noted that the ovaries of 50,000 sows were
required to isolate 20 mg of pure corpus luteum hormone.
At about the same time, some early studies on equine steroids in
urine and tissues were underway. Haslewood et al. (1934) noted that
pregnant mare urine contained a substance that appeared to have
properties similar to the pregnane-diol previously identified in pregnant
women's urine.Somewhat later, Brooks et al. (1952) identified two
progestins of pregnant mare urine to be 5a-pregnane-30,20a-diol and
5a-pregnane-313,200-diol, and isolated an additional seven progestins of
undetermined structure.Chromatography and ultraviolet absorption
spectrophotometry were methods used in these discoveries.
Short(1959)usedpaperchromatographyandultraviolet
absorption spectrophotometry methods with a progesterone detection
limit of 4 ng/ml (described in Short, 1958).He determined that the
placental tissues of mares had high levels of progesterone, but was3
unable to detect it in the uterine venous blood or in jugular blood of the
mare in later gestation (120 to 310 d).Interestingly, Short (1959) also
reported progesterone to be in the umbilical cord blood, and postulated
that during later stages of gestation, pregnancy was maintained by a
local effect of placental progesterone on the uterus.It was also
concluded that the reduced progestins identified in the mare's urine in
late-pregnancy may reflecttheshiftfromovariantoplacental
productionofprogesterone,andpossiblythetransferofthe
progesterone metabolic site from the mare's liver, and other maternal
organs, to the uterus.
It was not untilthe1960's that more intense research on
progesterone began.Progesterone had long been associated with
pregnancy maintenance, due to its ability to decrease the excitability of
the myometrium (Pearlman, 1948).In the 1950's and 1960's it was
discoveredthatinadditiontoits"progestational"qualities,
progesterone held inhibitory properties for the gonadotropins and was a
feasible human contraceptive (Garcia and Pincus,1964). Then much
interest was given to steroid research in all species.In the early
1960's, a number of radioimmunoassays (RIA) and improved competitive
protein binding assays (CPB) were developed, which weremore
sensitivethanprevioustechniques,andallowedtheroutine
measurement of progesterone, as well as other steroids, even at low
levels. The scientific literature of the years that followed was filled
with steroid hormone profiles throughout the estrous cycle and during
gestation for horses and other livestock species.4
2. General Reproductive Endocrinology of Mares
A complete discussionofreproductioninthemare, with
supporting research cited, isin the recent edition of Reproductive
Biology of the Mare (Ginther, 1992). In addition, a general account of the
basic endocrine parameters inthe cyclic and pregnant mare are
discussed in a review by Hyland (1990). This section is a brief summary
of general reproductive endocrinology of the mare, as noted from these
two references.
The mean length of the estrous cycle in the mare is 21.7 d, with
the mean lengths of diestrus being 14.9 d and estrus 6.5 d.Mean
duration of gestation is 340 d, but can vary from 310 to 374 d.A
number of hormones are associated with theestrous cycle and
pregnancy.
Reproductive hormones in mares fall under one of the following
structural categories: glycoproteins, proteins and peptides, fatty acids,
or steroids.The glycoprotein gonadotropins in the mare are equine
follicle stimulating hormone (eFSH), equine luteinizing hormone (eLH),
and equine chorionic gonadotropin (eCG). These hormones consist of both
an a and a a-subunit.The a-subunitisSimilar between each
gonadotropin, while the a-subunit is hormone specific.The equine
gonadotropins contain high concentrations of sialic acid, which is
thought to prolong hormone half-life and prevent rapid breakdown in the
liver.The decapeptide, gonadotropin releasing hormone (GnRH),is
produced and secreted from the hypothalamus and transported to the
anterior pituitary via the portal vessels, stimulating production and
release of eLH and eFSH. It is known that GnRH is released in a pulsatile5
fashion, and may therefore be responsible for the rythmic release of
both eLH and eFSH observed in mares.
Concentrations of eLH in peripheral circulation are low during
diestrus, and increase a few days prior to the onset of estrus. Maximum
concentrations are reached 1 or 2 d after ovulation, decreasing over the
next 4 to 5 d. Mean circulating eFSH levels are reciprocally related to
the eLH levels during diestrus. Peak concentrations of eFSH are noted in
diestrus. The eFSH stimulates the development of follicles, while eLH
is responsible for the final growth of the follicle and ovulation.
Cells of trophoblastic origin which form the endometrial cups of
the pregnant mare produce eCG from approximately 40 d gestation to a
peak between 55 and 65 d, with unelectable or very low levels by 100 to
150 d.The function of eCG is not completely understood.Due to its
characteristics, which are similar to both eFSH and eLH, eCG may be
responsible for the formation of secondary corpora lutea of pregnancy.
Immunological protection of the fetus from the mother may be mediated
with eCG. Murphy and Martinuk (1991) published a complete review on
this unique hormone in the mare.
A variety of peptide and protein hormones, in addition to GnRH
which was mentioned previously, have been identified in the mare
(referenced from Ginther, 1992). Oxytocin, an octapeptide, is produced
by the hypothalamus and stored in the posterior pituitary.In domestic
ruminants, oxytocin is also produced in the corpus luteum.In the
pregnantmare,oxytocinstimulatesmilklet-downanduterine
contractions at the time of birth.Oxytocin may also be involved with
prostaglandin release at the time ofluteolysisincyclic mares.
Prolactin, a 199 amino acid hormone, is produced by the anterior6
pituitary.Its functions in the pregnant mare appear to be primarily
mammary gland development and milk secretion. Relaxin, a polypeptide
produced in the uterus and placenta of pregnant mares, is important in
the preparation for birth.Inhibin, which is produced by follicles,
appears to selectively inhibit eFSH.Opioids are a family of peptides
produced in the brain and have suppressive effects on gonadotropin
secretion.Melatoninis known tobeinvolved with seasonality
regulation. This indole hormone is produced in the pineal gland.
Prostaglandins are 20-carbon fatty acids synthesized by a variety
oftissues.The primary prostaglandininvolvedinreproductive
processes is PGF2a. Due to its short half life, a metabolite of PGF2a,
known as PGFM, is used in assay systems to monitor peripheral levels.
In the cyclic mare, sharp peaks of PGFM are noted 14 to 17 d post-
ovulation, coincidental with luteolysis.Prostaglandins also cause
smooth muscle contractions.
The numerous steroids in the mare are all derived from the
common precursor, 30 -hydroxy-5-cholestene (cholesterol).
Steroidogenic pathways of steroids include enzymatic conversions of
cholesterol to 313-hydroxy-5-pregnen-20-one (pregnenolone), and then to
progesterone.Several pathways may be possible from progesterone.
Progesterone can be converted to 17a-hydroxy-4-pregnene-3,20-dione,
whichcanthenbemetabolizedto4-androstene-3,17-dione
(androstenedione) and the various estrogens (3-hydroxy-1,3,5(10)-
estratri en-17-oneorestrone,1,3,5( 10)-estratri ene-3,1713-di olor
estradiol, and 1,3,5(10)-estratriene-3,16a,1713 -triol or estriol).An
alternate pathway of metabolism may be from progesterone to 20a-
hydroxy-4-pregnen-3-oneorSa-pregnane-3,20-dione,followedby7
hydroxylations to form other progestin metabolites. The third pathway
from progesterone is to the various corticosteroids. Theprogestins,
estrogens, and androgens are the steroid groups of importance in
reproduction in mares. Sources of these steroids are many, but include
ovarian follicles, corpora lutea, adrenal cortex, placenta, and the feto-
placental unit.
The ovarian follicles produce estrogens (primarily estradiol)
commencing approximately 7 d prior to ovulation, with a peak estradiol
concentration noted in the peripheral circulation at 2 d prior to
ovulation.Peripheral concentrations are low during diestrus.The
corpus luteum produces progesterone which increases in the peripheral
circulation 1 d after ovulation. Concentrations reach a maximum within
approximately 5 d after ovulation and are maintained until 13 or 14 d,
when luteolysis occurs.
Large quantities of estrogens are produced in the pregnant mare
and excreted in the urine.In the mare, unlike most other species,
estrogen secretion decreases towards the end of pregnancy.Estrone
sulphate is produced from approximately 37 to 200 d, with a rapid
increase between 70 and 200 d. The source of early pregnancy estrogens
(35 to 40 d) appears to be primarily the maternal ovary's corpus luteum
(Daels et al., 1991).In later pregnancy, during the third month to the
seventh or eighth month, the feto-placental unit is involved in the
production of estrogens. From approximately 200 d to term a decrease
is noted in both plasma and urinary estrogens (Ginther, 1992).
Progesterone, from the corpus luteum, increases after ovulation
in both pregnant and non-pregnant mares.In the pregnant mare, these
levels are maintained with a slight decrease to 30 d noted. The increase8
to maximum levels between 60 and 120 d of gestation is due to
secondary ovulations as well as progestin contributions from the feto-
placental unit. Low levels are attained between 180 to 300 d gestation,
after corpus luteum regression. The feto-placental unit contributes to
the progestin pool from 60 or 70 d and throughout gestation with an
increase observed during the last 30 d of pregnancy. The progestins of
the pregnant mare will be discussed in greater detail in the following
section.
3. Progestins in Mares
In a series of four projects, Bhavnani et al. (1969 to 1973)
infused a number ofisotopicallylabelledprecursor andsteroid
compounds (7-3H-dehydroisoandrosterone, 4-14C-androstenedione, 14C-
acetate, 3H-cholesterol, 14C-squalene, and 14C-mevalonic acid) into the
umbilical vessels of pregnant mares, and monitored the radiolabelled
steroid metabolites excreted in the mare's urine using paper and thin
layer chromatography (TLC) methods. In the first two studies (Bhavnani
et al., 1969 and 1971), attention was focussed on estrogen formation.
In the last two studies (Bhavnani et al.,1973a,b), both estrogen and
progestin metabolites were analyzed. Their reports indicated that 30-
hydroxy-5a-pregnan-20-one,5a-pregnane-30,200-diol, and5a-
pregnane-30,20a-diol, derived from14C-squalene (Bhavnanietal.,
1973b) and from 14C-mevalonic acid (Bhavnani et al., 1973a), were the
predominant progestins in the urine of the pregnant mare. These studies
verified portions of the metabolic pathways for both the estrogens and
progestins.9
Inthe1970's,numerousreportsofthemare'splasma
progesterone profiles during the estrous cycle and pregnancy were
determined using either CPB or RIA.Smith et al. (1970), Plotka et al.
(1972), and Stabenfeldt et al. (1972), all indicated that in the non-
pregnant, cycling mare, plasma progesterone concentrations determined
with CPB, were at <1 ng/ml during estrus and increased to 5 to 8 ng/ml
at 5 to 10 d after ovulation.These higher levels were maintained
briefly, and decreased to <1 ng/ml after luteolysis. This basic profile of
progesterone during the estrous cycle is still accepted today.
Levels of plasma progesterone during pregnancy were reported by
several groups. Allen and Hadley (1973), and Van Niekerk et al. (1973),
bothutilizing CPB assays,examinedearlygestationandfound
progesterone increased initially (6 to 17 ng/ml), but a gradual decrease
was then observed. Allen and Hadley (1973) observed the decrease from
20 to 30 d of gestation, while Van Niekerk et al. (1973) observed
progesteronetodecreaseinconcentrationfrom10to14d
(approximately 2 ng/ml), with an increase in concentration from 17 to
30 d (approximately 4 ng/ml).
The following year, Squires et al. (1974), using a RIA, reported
that plasma progesterone concentrations during pregnancy decreased
between 7 and 19 d (10 to 8 ng/ml), increased rapidly from 32 to 44 d
with maximum concentrations at 90 d (15 ng/ml).A decrease to 10
ng/ml occurred between 150 to 180 d.Smith (1974) indicated that
plasma progesterone, determined with a CPB assay,increasedin
concentration with some variations between animals, during the first
60 d of pregnancy, decreased to a minimum at 180 d, and then reached
the maximum level of 11.5 ng/ml (significantly higher than the mean for10
the whole gestation of 7.6 ng/ml) from 270 d to term.Using a RIA,
Burns and Fleeger (1975) determined that during the last 90 d of
gestation, plasma progestins increased from 25 ng/mlat 90 d
prepartum, to 60 ng /ml at 10 d before foaling, with a slight decrease
within days prior to delivery.
The general trend for early gestation progesterone levels appears
to be an initial increase after ovulation, followed by a decrease at 30 d,
with a subsequent increase. The variations reported in early gestation
in the various studies were minor, and probably due to animal and assay
variations. However, there appeared to be some major discrepencies in
the literature regarding progesterone levels of later pregnancy.With
Short's report (1959) indicating that no progesterone was inthe
systemic circulation of mares In late-gestation, it would seem that
these more recent assays may be over-estimating the amounts of
progesterone in later pregnancy.
Holtan et al. (1975b,c) purified the samples with Sephadex LH-20
column chromatography prior to analysis in CPB assays, and verified
that high concentrations of progesterone existed in early pregnancy up
to 150 d, as was previously reported. A maximum concentration of 15.2
ng/ml was attained at 64 d.However, in contrast to the other studies,
at 180 to 300 d, only 2 ng/ml of progesterone was reported with an
increase to 4 ng/ml in the last 30 d of gestation.In addition, these
investigatorsfoundverylowconcentrationsof17a-hydroxy-4-
pregnene-3,20-dione except between 40 and 120 d, and during the last
30 d of gestation. Two fractions were reported to first appear between
30 and 60 d of gestation and increase gradually to 300 d, followed by a11
rapid gain in concentration to parturition.Both compounds were noted
to cross-react with two different RI A's for progesterone.
Another group (Ganjam et al., 1975) determined with both RIA and
CPB assay that there were two peaks of plasma progestins; one in the
third month which coincided with eCG secretion and secondary corpus
luteum formation, and the other in the eleventh month and probably from
placental sources.After purification, the levels of progesterone
reported by these CPB assays for later pregnancy were reduced, but still
present. These researchers also speculated that unknown metabolites of
progesterone may be contributing to the progesterone levels in late-
pregnancy.In a study conducted by Barnes et al. (1975) using TLC and
RIA, jugular vein samples were analyzed, and fetal samples were also
collected via indwelling catheters.They indicated that progestins,
which may include progesterone metabolites, were present in high
concentrations in both fetal and maternal samples.
The unidentified progestins reported to be present in the later
stages of gestation were identified with gas chromatography/mass
spectrometry (GC/MS) by both Atkins et al. (1974) and Holtan et al.
(1975a).Atkins et al. (1974) identified 5a-pregnane-3,20-dione, and
indicated that progesterone declinedin concentration during late-
gestation.Additionally, they claimed 20a-hydroxy-4-pregnen-3-one
was measurable with RIA.Holtan etal.(1975a) identified 5a-
pregnane-3,20-dione, 313-hydroxy-5a-pregnan-20-one, and 20a-hydroxy-
5a-pregnan-20-one in pregnant mare circulation, from both intact and
ovariectomized mares, as well as in umbilical vessel blood.High
amounts of progesterone were found in placental tissues.Holtan et al.
(1975a) postulated that since these three pregnanes identified were12
much higher in the fetal vessels compared to the maternal circulation,
the feto-placental unit was the most probable source. However, Atkins
et al. (1976) using RIA and GC/MS found 5a-pregnane-3,20-dione in the
peripheral plasma of cyclic and pregnant mares during the first 150 d of
pregnancy. They therefore concluded that possibly the ovary in early
pregnancy, as well as the feto-placental unit in later gestation produce
5a-pregnane-3,20-dione.
Seamans et al. (1979), using column chromatography and a RIA
with a nonspecific antibody, found high levels (133 ng/ml) of 5a-
pregnane-3,20-dione 80 h prior to parturition, with a decline following
this peak. This group also reported a combined hydroxy-5a-pregnanone
fraction at concentrations in excess of 1600 ng/ml up to 8 h before
foaling. Progesterone levels were in the range of 4 to 8 ng/ml at the
time of foaling according to their report.Moss et al. (1979) infused
[1,2,6,7-3H] progesterone into the uterine artery of pregnant mares or
umbilical vein, and collected samples from indwelling catheters in
uterine and fetal vessels. Using TLC to isolate the various progestins,
more radioactive 5a-pregnane-3,20-dione was found in the fetal vein
samples than the other vessels.Higher levels of radioactive 3p-
hydroxy-5a-pregnan-20-one were found in the fetal artery, and more
radioactive 20a-hydroxy-5a-pregnan-20-one was noted in the maternal
vessels. They concluded that 5a-pregnane-3,20-dione was produced by
theplacenta,20a-hydroxy-5a-pregnan-20-one was from maternal
sources, and 3p-hydroxy-5a-pregnan-20-one from the fetus primarily.
Seren et al. (1981) investigated progesterone, 17a-hydroxy-4-
pregnene-3,20-dioneand20a-hydroxy-4-pregnen-3-onelevelsin
pregnant mare plasma, using rather non-specific antibodies in RIA13
systems.The 17a-hydroxy-4-pregnene-3,20-dione and progesterone
were higher in the second and third months of pregnancy which coincides
with elevated eCG levels and secondary luteinizations.Concentrations
of 20a-hydroxy-4-pregnen-3-one were noted to be low (2 ng/ml) during
the first three months of pregnancy, with a rise beginning in the fifth
month, and even higher levels (80 to 120 ng/ml) were attained in the
last month of gestation suggesting a source other than the ovary.This
study indicated that their antibody for 20a-hydroxy-4-pregnene-3-one
cross-reactedwith20a-hydroxy-5a-pregnan-3-one,whichwas
previously noted to be high near parturition.Therefore, the levels
indicated may include a contribution by the 5a-pregnane metabolite.
Holtan et al. (1979) found that the ovaries are dispensable after
50 to 70 d of gestation, as determined by ovariectomy of pregnant
mares.This work therefore further supported the varying sources of
these additional progestins in later pregnancy.It was indicated from
this study that the placenta was the most probable source of progestins
to maintain pregnancy after 50 to 70 d.Prior to this time, ovarian
progesterone was essential to pregnancy maintenance. Pashen and Allen
(1979) foundthat removaloffetalgonadsdidnotaffectthe
concentrations of progestins, and pregnancy was maintained. However,
theydidnoticeestrogensdecreasedimmediatelyafterfetal
gonadectomy, and PGF2a metabolite (PGFM) were depressed at the time
of foaling.Gonadectomized foals were dysmature and died soon after
birth.Mares carrying these foals had weak uterine contractions and
required assistance in foaling.This report suggested that the fetal
gonad supplies precursors for estrogen metabolism which occurs in the14
placenta.Without these estrogens fetal development isimpaired.
Estrogens prime the uterus to produce prostaglandins and activate
oxytocin receptors at birth.Therefore, the lack of estrogens probably
causedtheweakeruterinecontractionsinthemareswith
gonadectomized foals.Progestins by contrast were not affected, thus
they must be produced and metabolized independent of the fetal gonads.
Several progesterone metabolites have been identified in late-
gestation.Without doubt the high levels of progesterone noted in the
later stages of the equine pregnancy by several researchers were due to
non-specificcross-reactivityofthevariousprogestinswith
progesterone antiserum in RIA and CPB assays.GC/MS techniques
developed for steroid analysis (see discussion in the following section)
were the solution to the cross-reactivity problems associated with
immunoassays.Definitive identification of the various progestins is
attained using molecular weights and specific ions indicating the
predictable breakdown fragments.
Holtanetal.(1991) performed anextensiveinvestigation
utilizingGC/MSanddeuteriumlabelledinternalstandards.
Identification of three 5-pregnenes, two 4-pregnenes, and seven 5a-
pregnanes were reported.Eight of these progestins were examined
throughout pregnancy in the mare.The predominant progestinsin
pregnant mare jugular vein plasma near term were 20a-hydroxy-5a-
pregnan-3-one (400 to 2100 ng/ml) and 5a-pregnane-313,20a-diol (100
to 350 ng/ml).These two steroids,in addition to four more 5a-
pregnanes (30 to 100 ng/ml), were initially detected between 30 and 60
d of gestation, and increased gradually throughout pregnancy with a
rapid increase observed in the last 30 d prior to foaling.Progesterone15
levels were similar to all previous reports for early gestation, but it
was at undetectable levels (assay sensitivity was at least 0.5 ng/ml)
during mid- to late-pregnancy.Samples obtained from Indwelling
catheters in the fetal and maternal vessels of late-gestation mares
(250 to 300 d) were also analyzed in this study.Fetal artery steroids
were: pregnenolone (422 ng/ml), 5-pregnene-313,2013 -diol (171 ng/ml),
30-hydroxy-513-pregnan-20-one (277 ng/ml), and 5a-pregnane-313,2013-
diol (221 ng/ml). The predominant steroid of the fetal vein was 5a-
pregnane-3,20-dione (205 ng/ml), with low but detectable progesterone
(12.7 ng /ml). The jugular vein concentrations, as described above, were
similar to the uterine arteriallevels,and the uterine vein had
approximately double those amounts.These data suggested that the
fetus produces pregnenolone which is metabolized to progesterone and
513-pregnane-3,20-dionebytheplacenta,with313-and2013-
hydroxylations accomplished by thefetus, and 20a-hydroxylations
occurring in the mare endometrium.
Progestin concentrations have been noted to change in abnormal
pregnancies. Decreased progestins associated with complications during
pregnancy were observed in studies using non-specific RIA systems
(Ousey et al., 1987; and Santschi et al., 1991). It has also been reported
by Holtan et al. (1991) using both GC/MS and RIA methods that mares
delivering prematurely or aborting have decreasing pregnane levels, in
particular 20a-hydroxy-5a-pregnan-3-one. Inastudy concerning
progestins of normal and dysmature foals (Houghton et al., 1991), it was
determined that pregnenolone and 5- pregnene 313,2013 -diol were higher
in premature foals.A recent study (Rossdale et al.,1992) found
increases in maternal plasma progestins following injections of adrenal16
stimulants to the fetal circulation, indicating that the fetus may be
involved with normal progestin production.It is probable that levels of
certain progestins in the late-gestation mare may be found to reflect
the fetal status, and be useful in identifying problems during pregnancy,
orimpendingabortions. Moreresearchisneededtoconfirm
concentrations of the various progestins in both maternal and fetal
systems throughout gestation in both normal and abnormal pregnancies.
4. Development of GC/MS Methods for Steroid Analysis
Concerns regardingthe useofbothanabolicsteroids and
corticosteroids to enhance performance in race horses were apparent in
the 1970's. Similar problems were of course being experienced in human
athleticevents. Methodstodetectthesehormones,ortheir
metabolites, in urine and blood were developed to monitor this problem.
The GC/MS analysis of pregnant women's urine was already used
routinely.Swedish scientists had used GC/MS to identify numerous
metabolites (5a and 50-pregnane-diols, -triols, and -tetrols as well as
pregnene-diols) in pregnant women's urine and fecal samples (Eriksson
and Gustafsson, 1970; Eriksson et al., 1970; and Janne and Vihko, 1970).
Eriksson and Gustafsson (1970) analyzed urine from a woman in her 37th
wk of pregnancy, while Eriksson et al. (1970) analysed fecal samples
from the same individual. The majority (88%) of pregnane-diols in urine
were free and glucuronide fractions of the 5ri configuration, whereas the
remaining 12% of the pregnane-diols were di-sulphated 5a configurated
compounds. Fecal pregnane-diols in the di-sulphated fractions were of
the 5a configuration, whereas both 5a and 50 isomers were present in
the free steroid fraction.Janne and Vihko (1970) identified three17
hydroxyl ated progestins (313,15a-dihydroxy-5a-pregnan-20-one, 30,15a-
dihydroxy-50-pregnan-20-one, and 5-pregnene-30,1513,17a,20a-tetro1)
in pregnant women's urine.They suggested that15-hydroxylated
progestins, which were suspected to be formed from progesterone in the
feto-placental unit, may be useful in monitoring fetal well-being.
The methods for GC/MS identification of progestins have been
improved overtimewithsolidphaseextractionprotocolsand
purification techniques, and applied to plasma and tissue samples
(SjovallandAxelson,1979;andAxelsonandSahlberg1983).
Incorporation of deuterium labelling procedures to analyze metabolism
of the progesterone in humans has also been developed(Bail lie et al.,
1980; and Anderson et al., 1990). These two groups injected deuterium
labelled precursor steroids intravenously to pregnant women, and
collected blood periodically. Baillie et al. (1980) noted that the primary
metabolic product in pregnant women was 5a-pregnane-30,20a-diol.
Anderson et al. (1990) determined 5a-pregnane-3a,20a-diol and 3a-
hydroxy-5a-pregnan-20-one were the predominant products of progestin
metabolism in pregnant women.
During the late 1970's and 1980's, GC/MS protocols were modified
in order to detect a variety of steroids (androgen and corticosteroid
metabolites) in horses, primarily in urine (Houghton et al., 1984, 1988;
and Dumasia et al., 1986, 1989).These methods were subsequently
applied in additional steroid studies in horses incorporating stable
deuterium isotopes (Houghton et al., 1990). Holtan et al. (1991) included
a detailed protocol which was successfully used in identifying and
quantifying plasma progestins of the pregnant mare and fetus.18
5. Tissue Incubation Studies
Tissue incubation studies are frequently useful in determining
enzyme system locations.Although the data generated from such
studies are limited since isolated systems are analyzed, some important
findings have been published from such studies.Ainsworth and Ryan
(1969) incubated placental tissue from a pony mare with either
pregnenolone-7a-3H or progesterone-4-14C.The placentaltissue
converted radioactive pregnenoloneto progesterone. Inaddition,
radioactive pregnenolone and progesterone were metabolized to 20a-
hydroxy-4-pregnen-3-one,5a-pregnane-3,20-dione, 313-hydroxy-5a-
pregnan-20-one, 20a-hydroxy-5a-pregnan-3-one, 5a-pregnane-313,20a-
diol,and5a-pregnane-313,17a,20a-triol,asdeterminedwith
chromatography.
Although usefulinidentifying enzymesintissue,limited
histochemical work has been done with equine tissues.A study
published in 1975 (Flood and Marrable) addressed the distribution of
several hydroxysteroid dehydrogenases (HSD), in a variety of equine
placental and fetal tissues. They noted HSD to be present in placental
and uterine tissues in all stages of pregnancy.
A recent study conducted by Hamon et al. (1991) determined from
fetal and maternal tissue incubations that 5a-pregnane-3,20-dione
production was derived primarily from endometrial metabolism of
pregnenolone and progesterone.Placenta converted pregnenolone to
progesterone.Negligible amounts of 5a-pregnane-3,20-dione were
produced by fetal tissues (adrenal, liver, or testes).In this study, an19
enzyme immunoassay (EIA) was developed with a specific antibody for
5a-pregnane-3,20-dione.
Marshall et al. (1991) determined from tissue incubations, that
the source of extra-ovarian estrogens was the placenta.Incubations of
fetal and maternal tissues with deuterium-enriched 170-hydroxy-4-
androsten-3-one (testosterone) and [4-14C] testosterone allowed the
identification of estrogen metabolism capabilities ofthetissue.
Chromatography and GC/MS methods were used in the identification of
isotopically labelled estrogens in the placental tissues, indicating that
this was the location of the majority of aromatase activity.
Tissue incubations have also been utilized to study steroid
metabolism in other species. A study on the human placenta (Rabe et al.,
1985), indicated that rates of synthesis of placental progesterone in
vitro were autoregulated, and dependent on metabolic endproducts
affecting the enzyme systems.In other studies (Powell and Challis,
1986; and Powell et al., 1986), human chorion tissues were used for
incubation experiments.It was noted again in these two studies that
various steroids can modulate the amount of progesterone produced in
the chorion by affecting the enzymes involved.it was indicated that
these steroids exert their control through the enzyme 313-hydroxysteroid
dehydrogenase, with 20a-hydroxy-4-pregnen-3-one being stimulatory to
progesterone production, while testosterone, androstenedione, and 313-
hydroxy-5-androsten-17-one (dehydroepiandrosterone) were inhibitory.
It was noted in these reports that the autoregulatory systems may be
involved with the process of parturition in humans, by exerting local,
paracrine effects on prostaglandin production.Possibly this type of
control mechanism exists in other species as well.20
Numerous studies have been completed using laboratory animals.
Lerner and Eckstein (1976) determined that the immature rat ovary
metabolizedinvitro5a-androstane-3a,1713-diol, 3a-hydroxy-5a-
pregnan-20-oneand3a,17a-dihydroxy-5a-pregnan-20-one. This
metabolism is characteristic only until puberty, when the metabolic
capabilities change.It is possible that while still in utero, the late-
gestation fetal gonad may be metabolically similar to the ovaries of
these immature rats, and contribute to the progestins produced, as well
as providing precursors for estrogen production in the placenta.
When rats were infused with radiolabelled progesterone, and
subsequently the uterus removed and examined for progestins, it was
noted thatboththe myometrium and endometrium take up and
metabolize progesterone, with the amount dependent on the stage of the
estrous cycle or pseudopregnancy (Redmond and Pepe,1986).The
endometrium metabolized more progesterone during pseudopregnancy
than during the estrous cycle.They concluded that endometrial
differentiationassociatedwithpseudopregnancyappearstobe
associated with increased progesterone and its reduced or hydroxylated
metabol ites.
In a study using rabbits, animals of both sexes were infused 1.v. or
i.p. with radioactive progesterone and then killed 10 to 45 min later
(Sendai] and Roberts, 1989).Various tissues, blood, and urine were
collected and tested for steroid content.They noted that the 21-
hydroxy-stero i dmetabolites(21-hydroxy-4-pregnene-3,20-di one,
3a,21-dihydroxy-513-pregnan-20-one, 3a,2013,21-trihydroxy-513-
pregnane, and 3a,6a,21-trihydroxy-513-pregnan-20-one) derived from
progesterone were found in the liver, kidney, and urine.21
Uterine endometrium from sows in mid-luteal phase of the
estrous cycle was found to metabolize radioactive progesterone in vitro
to ten progestins, of which two were identified to be5a-pregnane-
3,20-dione and 311-hydroxy-5a-pregnan-20-one (Hendricks and Tindall,
1971).These researchers thought that it was possible that the 5a-
reduction of progesterone may be necessary for it to exert its biological
effects on the endometrium. They indicated that this type of situation
exists in males where testosterone is converted to 17a-hydroxy-5a-
androstan-3-one in order to exert its effects on the prostate.
In another study, it was noted that porcine steroidogenesis in the
placental incubations varied throughout gestation, but appeared to be
local metabolism since the variation was not observableinthe
peripheral circulation of the sow (Kukoly et al.,1984).Fisher et al.
(1985) demonstrated that in endometrial and conceptus tissues from
sows at 10 to 25 d of gestation, there were temporal changes in the
conversion of progesterone to estrogens, which was not observed in
pseudopregnant gilt endometrium. The ability of both the endometrium
and conceptus to convert progesterone to estrogens may be important to
maintenance of pregnancy in pigs.This group also demonstrated that
radioactiveprogesteronewas convertedtonon-polarprogestin
metabolites, not estrogens, in endometrium of pseudopregnant gilts.
The presence of the conceptus appears to be necessary for estrogen
production at this stage of pregnancy in swine and possibly other
species as well.
The sources of progestins vary between species and at various
stages of gestation.It has been well documented that ovariectomy of
rats, rabbits, pigs, and goats in any stage of pregnancy results in22
abortion,duetodependency onthe primary corpusluteumfor
progesterone.However,inprimates,horses,cattle,and sheep,
ovariectomy after early pregnancy does not cause abortion, since the
placenta produces progestins (Short, 1969).
Sheidrick et al. (1981) incubated placental cotyledons from sheep
and goats, and determined that goat placental tissue was three times
more active in progesterone metabolism than sheep placental tissue.
Peripheral plasma concentrations of 50-pregnane-3a,20a-diol in goats
were similar to progesterone concentrations in sheep.Wango et al.
(1991) demonstrated that isolated fetal placental binucleate cells
(specialized trophoblastic cells) in sheep produce progesterone, whereas
goatsproduce50-pregnane-3a,20a-diolpredominately. This
metabolism of progesterone could account for the placenta of goats
being unable to maintain pregnancy after ovariectomy. A study by Wango
et al. (1992), indicated that the sheep placental binucleate cells utilize
both the cyclooxygenase and lipoxygenase pathways of the arachidonic
acid metabolism to regulate placental steroid production, whereas goat
placental cells use only the lipoxygenase pathway.This observation
indicates that the mode of steroid regulation may differ in the two
species, resulting in different progestins predominating.
In cattle, Shemesh et al. (1983) determined that placentomes
from cows at 100 to 150 d of gestation, comprised of both fetal and
maternaltissue,couldsecretearegulatoryproteintocontrol
progesterone production in co-incubated granulosa and luteal cells. This
inhibitory protein may alsoplayaroleinregulatingplacental
steroidogenesis.In other research, bovine binucleate trophoblastic
placentalcells were notedtobe capableofmetabolizing both23
progesterone and prostaglandins, an apparent autoregulation (Reimers et
al., 1985).
In the tissue incubation studies that have been discussed here, it
would appear that some important information relevant to progestin
metabolism has been generated.However, systematic approaches to
analyze each component to the overall scheme of steroid metabolism
during pregnancy, in each species, have yet to be undertaken.In
addition,thebiologicalsignificance,ifany,oftheprogestin
metabolites has not been examined sufficiently.
6. Biological Activity of Progestins
Research in mares has concentrated on progesterone's role in
controllingeLHsecretionandestroussynchronization,andthe
importance of progesterone to pregnancy maintenance, withlittle
concern to the functional significance of the other progestins found in
the mare.If these progestins have any biological activity, it may be
significant since some are found at concentrations approximately 100 to
1000 times greater than progesterone during late-pregnancy.
As noted previously in this review, during the 1950's and 1960's
interest was focussed on the fact that progesterone was inhibitory to
the gonadotropins. Determination of the negative feedback properties of
progesterone on eLHinmares has been documented byseveral
researchers.In ovariectomized mares, Garcia and Ginther (1978)
determined that exogenous progesterone inhibited the secretion of eLH
during the summer breeding season.It was also noted that estradiol, in
conjunction with progesterone, had even greater inhibitory effects on
eLH. However, estradiol alone was stimulatory to eLH. Thompson et al.24
(1991) determined, from an extensive study examining the effects of
severalsteroids on gonadotropins,that progesterone doesindeed
possess inhibitory regulation properties to eLH in the ovariectomized
mare.
In ovarian intact mares, a study conducted by Evans et al. (1982),
found that progesterone alone inhibited eLH in cyclic mares, and if
progesterone and estradiol were administered together, even greater
inhibition of eLH was observed.Silvia etal.(1987) found that
exogenous estradiol with endogenous progesterone did not inhibit eLH
more than in the animals with endogenous progesterone only. Therefore,
in the mare, there is substantial evidence for progesterone's inhibitory
control on eLH.The precise mechanism for this control, and the
effectiveness of other progestins to act similarly needs further
investigation.
During the 1970's and 1980's, great efforts were directed to more
efficiently managing reproductioninmares.The applicationof
progesterone's inhibitory properties on the gonadotropins, thus estrus
and ovulation, was utilized in these management programs.It was Loy
and Swan (1966), that originally noted the usefulness of progesterone in
synchronizing ovulation in mares. Dosages of 100 mg/d of progesterone
in oil, injected i.m., beginning in the mid-luteal phase of the estrous
cycle and continuing to 19 or 20 d post-ovulation, in nonpregnant mares,
inhibited estrus and ovulation in all mares.Four of the six treated
mares ovulated 6 d after the withdraw] of treatments.In postpartum
mares treated with the same dosage from 4 through 12 d postpartum,
all six mares showed inhibition of estrus and ovulation until treatment
was withdrawn.Additionally, lower dosages of progesterone, 6a-25
methyl -17a-acetoxyprogesterone (MAP) injected i.m., and melengestrol
acetate (MGA) or MAP fed orally were all shown to be ineffective in
inhibiting estrus and ovulation. MGA and MAP are synthetic progestins
that had been used successfully in other species to inhibit estrus and
ovulation.
Webel (1975) determined that an orally administered synthetic
progestin(173 -hydroxy-4,9,11-estratrien-3-one) was effectivein
controlling estrus. Several studies followed (Palmer, 1979; Squires et
al., 1979; Webel and Squires, 1982; and Squires et al.,1983) which
further validated this progestin's effectiveness in control of estrus.In
1984, this synthetic progestin (Altrenogest®) was approved in the
United States for commercialuse to control estrus and ovulation in
mares.
The inclusion of a prostaglandin injection at the end of progestin
therapy, to induce luteolysis, andan injection of human chorionic
gonadotropin (hCG) in the presence of a large follicle in the estrus that
ensues after the progestin and prostaglandin treatments, provides even
greater control of estrus and ovulation. (Holtan et al., 1977; Taylor et
al., 1982).Excessive use of hCG should however, be cautioned due to
antibody development, whichin some mares causes a refractory
response to subsequent treatments with the hormone (Roser et al., 1979;
and Wilson et al., 1990).
Similar programs for progestin treatment in postpartum mares to
delay foal heat have also been reported (Loy et al., 1975, 1982;Bristol
et al., 1983; and Bell and Bristol, 1987). A study by Parry-Weeks and
Holtan (1987), found Altrenogest® to be useful in synchronizing equine26
embryo recipients and maintaining pregnancy.Luteal progesterone is
essential to the maintenance of early pregnancy, as was demonstrated
by Holtan et al. (1979) and Kastelic et al. (1987).Consequently, it has
become a common practice of breeding farms to supplement problem
mares with an exogenous progestin source (Shideler et al., 1982; and
Jackson etal.,1986).The effectiveness of providing exogenous
progesterone to pregnant mares was scrutinized by Allen (1984). Allen
questions whether the declining progesterone in early pregnancy causes
the mare toabort,orifthemalfunctioningfetuscausesthe
progesterone to drop.It has been documented that in cases of surgical
removal of the conceptus or in spontaneous abortions after 40 d, eCG is
not capable of maintaining luteal function in all mares, suggesting the
existance of a luteotropin from the conceptus (Allen, 1979). This is an
area which needs further investigation.
More extensive research in the area of biological actions of
progesterone and the various progestin metabolites have been completed
using the female rat as the model.Biological actions of progestins,
relative to pregnancy maintenance and gonadotropin regulation, have
been investigated.Sanyal and Villee (1973), found Sa-pregnane-3,20-
dione to have no progestational qualities in ovariectomized rats, but
that it was capable of supporting the free floating blastocyst.Only
progesterone was capable of initiating implantation and maintaining
pregnancy in these rats.
Sridharan et al. (1974) observed in female rats that pregnenolone,
progesterone,and5a-pregnane-3,20-dionewerefacilitativeto
ovulation. Larger amounts of pregnenolone and 5a-pregnane-3,20-dione
were needed to elicit the same response that progesterone caused.27
However, 3a-hydroxy-5a-pregnan-20-one was ineffective at even high
dosages.
Zanisi and Martini(1974) examined the effects of estrogen and
progesterone, as wellas 5a-pregnane-3,20-dione, 3a-hydroxy-5a-
pregnan-20-one, and 30-hydroxy-5a-pregnan-20-one on LH regulation in
ovariectomized female rats.Using various combinations of exogenous
hormones andestrogen implants in the hypothalamus and anterior
pituitary, they determined that progesterone and 5a-pregnane-3,20-
dione were more effective in modulating GnRH and subsequently LH, than
either 3a-hydroxy-5a-pregnan-20-one or 3p-hydroxy-5a-pregnan-20-
one.
Nuti and Karavolas (1977) found progesterone, 5a-pregnane-3,20-
dione, and 3a-hydroxy-5a-pregnan-20-one all to affect LH systemically
in rats.They suggested that since progesterone is converted to
metabolites suchastheseinneuroendocrinetissues,thatthe
metabolites may be involved with the positive and negative feedback
mechanisms on gonadotropins.
Krause and Karavolas (1980, and 1981) examined 5a-reductase
and 3a-hydroxy-steroid oxidoreductase enzymes in adult female rat
hypothalamic tissues.These enzymes convert progesterone to 3a-
hydroxy-5a-pregnan-20-onevia5a-pregnane-3,20-dione.Itwas
reported that 3a-hydroxy-5a-pregnan-20-one has modulatory effects on
the gonadotropins, but this may actually be through 5a-pregnane-3,20-
dione via a back conversion from 3a-hydroxy-5a-pregnan-20-one. From
studies such as these, it appears that progesterone metabolites may
play animportantroleintheregulationofthehypothalamo-28
hypophyseal-ovarian axis.More work will be necessary to further
address the complete mechanism involved, and to determine whether
similar mechanisms exist in other species.
Additional studies with rats have addressed the effects of
progestins on progesterone receptors and gamma amino butyric acid
(GABAA) receptors.Since GABAA receptors are abundant in the brain,
progestins binding to them may be directly controlling gonadotropins.
Morrow et al. (1987) and others indicated progesterone metabolites
interact with GABAA receptors of the brain.Brann et al. (1990) then
providedevidencethat3a-hydroxy-5a-pregnan-20-oneinduced
gonadotropin secretion was mediated by GABAA receptors in the brain.
Putnam et al. (1991) analyzed contraction control by progestins on
uterine tissue from rats, and found that both 313-hydroxy-5p-pregnan-
20-one and pregnane-diol are mediated through the GABAA system to the
uterus, but 513-pregnane-3,20-dione and progesterone use progesterone
receptors. The evidence that progestins use receptors other than the
progesterone receptor, may help explain the actions of the progesterone
metabolites. These mechanisms of action, at the receptor level, have
not been adequately addressed.
EMBRYO RESEARCH
1. Maternal Recognition of Pregnancy;
Steroids and Proteins of the Early Embryo
In the mare, 4 to 6 d after fertilization the zygote reaches the
uterus, while the numerous unfertilized eggs stay in the oviduct for
months, where they slowly degenerate (Short, 1969).The prolongation
of corpus luteum function, or maternal recognition of pregnancy, is of29
primary importance to the survival of this zygote in the uterus to allow
its further development throughout gestation.The mechanism of
pregnancy recognition in mares, and other species, appears to be rather
complex. This has been the topic of extensive research in the past, and
withmanyaspectsofthemechanismstillunclear,further
investigations are needed.
Maternal recognition of pregnancy in the mare is thought to occur
between 14 and 16 d post-ovulation (Hersham and Douglas, 1979). Other
studies have shown it may be as early as 11 to 13 d (Goff et al, 1987).
Steroids, in particular estrogens, have been analyzed in the early stages
of gestation in mares.Although estrogen levels in the first month of
gestation in mares resemble diestrus levels, the embryo is capable of
estrogen production as early as 7 d, with an actual increase between 12
and 20 d (Zavy et al., 1979 and 1984; Heap et al., 1982; and Marsan et
al.,1987).Goff et al. (1983) noted that estrogen production was
enhanced by the addition of blastocoel fluids to dispersed embryos in
vitroHeap et al. (1991) noted that chorionic girdle, yolk sac, and
allantochorion tissue contained varying amounts of aromatase activity
in horse embryos.The donkey conceptus, by contrast, has similar
aromatase activity in all tissues.The biological significance of high
aromatase activity, for the formation of estrogens in the horse and
donkey embryos, remains elusive.
Since the production of these estrogens (estrone, estradiol, as
well as androgens) occurs at the crucial time for the maintenance of
pregnancy, it has been proposed that they may be involved in maternal
recognition of pregnancy in the mare, as they are in the pig (Flint et al.
1979;Heap et al.,1981).However,it has been established that30
mechanisms in each species must differ since exogenous estrogens are
not luteotrophic in the mare (Allen, 1979), but are in the sow (Flint et
al., 1979). In addition to the secretion of estrone and estradiol from pig
blastocysts, several secretory proteinsarealsoproduced. These
proteins, when intralumenally infused in the sow, do not prolong the
corpus luteum lifespan (Bazer et al., 1986, 1989).Therefore, it would
seem the estrogens are indeed important in the sow's recognition of
pregnancy.
In the ewe and the cow, an interferon-like trophoblastic protein
isproducedbytheconceptuswhichreducesthereleaseof
prostaglandins from the uterus (imakawa et al., 1987; Stewart et al.,
1987, 1989; and Anthony et al., 1988).Wilson et al. (1992) have also
identified and quantified estrone, estradiol, and progesterone in bovine
embryos at the time of pregnancy recognition.Studies with mice (Wu,
1987; and Wu and LW, 1990) have shown that pre-implantation mouse
embryos can metabolize progesterone toits various metabolites,
indicating an extensive enzyme system. Similar systems may also exist
in livestock species.
The precise mechanism of maternal recognition of pregnancy in
mares is not certain. Undoubtedly, the steroid production of the equine
conceptus plays some role in the process. Marsan et al. (1987) noted
that after dissociation with collagenase, the horse conceptus at 12 to
15 d is composed of high density cells (trophectoderm) which secrete
primarilyestrogen,andlowdensitycells(endoderm)secreting
progesterone.The interactions of these two cell types are probably
crucial for steroid metabolism in equine embryos. This study used non-31
specific RIA systems which did not allow the definite identification of
the intermediate metabolites or the steroids measured.
Pregnancy signalling in the mare may involve several mechanisms
acting together to reduce prostaglandin release. When the conceptus is
in the uterus, lower prostaglandin concentrations are noted in the
uterine vein (Douglas and Ginther, 1976), uterine lumen (Zavy et al,,
1979, 1984), and the periphery (Kindahl et al.,1982). Since the co-
incubation of conceptus membranes and endometrium result in decreased
prostaglandin production from the endometrium,it is suggested the
mobility and contact of the embryo with the maternal endometrium is
important to pregnancy maintenance (Berg land et al.,1982; and Sharp et
al., 1984). Sharp et al. (1989) partially identified a protein they called
prostaglandin inhibitory factor which is transient, and its production
required conceptus mobility.Watson (1991) noted that mares possess
an intracellular inhibitor to prostaglandin in the endometrium which
may be produced in pregnancy.
In addition to questions surrounding the sustenance of luteal
function for pregnancy maintenance, thereisalackof evidence
indicatingpreciselyhowtheearlyembryoisprotectedfrom
immunological rejectionin most species.The cytotoxic antibody
response in the mother is directed towards paternal fetal antigens of
the major histocompatability complex (MHC). Antezak and Allen (1989)
noted that the source of fetal MHC in the equine pregnancy is the
trophoblast cells of the chorionic girdle which form the endometrial
cups. The progenitor girdle cells express high levels of paternal MHC,
while the non-invasive trophoblast cells of the allantochorion and the
cells of the mature endometrial cups do not express MHC. Additionally,32
Roth et al. (1990) identified an immunosuppressor factor from the
equine conceptus which is undoubtledly involvedinthis immuno-
protection of the fetus.The literature concerning mechanisms for
pregnancy recognition and maintenance in all species indicates that
many facts have been established, but much is yet unknown.
2. Plasminogen Activator Research
The early embryo in all species undergoes extensive cellular
remodeling,tissueproliferation,hatching,andimplantationor
placentationprocesseswhichallrequireenzymaticreactions.
Plasminogen activator is a protease produced by the blastocyst which
converts the zymogen plasminogen to the trypsin-like enzyme, plasmin
(Sherman et al., 1976).Plasminogen, which has been identified in the
uterine lumen of swine and murine species, is the source of protease
that the developing embryo controls by altering plasminogen activator
availability (Fazleabas et al., 1983; and Finley et al., 1983).
Mouse blastocysts have been shown to produce plasminogen
activator from trophoblast cells primarily (Sherman etal.,1976;
Strickland et al.,1976).These reports indicated that plasminogen
activator may participate in the invasive implantation of mice. Mullins
et al. (1980) identified plasminogen activator in swine conceptuses.
Thisgroupalsoidentifiedaprogesteroneinducedinhibitorto
plasminogen activator, which they thought may explain the non-invasive
implantation observed in swine.Fazleabas et al. (1983) found that
estrogens stimulate the swine blastocyst to elongate, which enhances
the release of plasmin inhibitors by the endometrium to control the
proteolytic reactions of plasminogen activator that potentially could33
damage the endometrium.This study indicated that the plasminogen
activator was involved in tissue reorganization and proliferation.
MeninoandWilliams(1987)determinedthatplasminogen
activator enhanced hatching of the bovine blastocyst.Two other
reports, (Domon et al., 1973; Menino and O'Claray, 1986) also indicated
that possibly plasminogen activator was involved with blastocyst
hatchingin the murine species.Plasminogen activator has been
characterized in the bovine species (Coates and Menino, 1991) and the
ovine species (Bartlett and Menino, 1991) to be an urokinase-type.
Plasminogen activator has been identified in the murine, ovine,
porcine, and bovine blastocyst.However, its precise mechanism of
action and purpose is still not completely understood. No research has
been published regarding plasminogen activator identification in the
equine embryo.
CURRENT OBJECTIVES:
In conclusion to this entire literature review, it would seem a
number of areas need further investigation. The research objectives of
this current research will focus primarily on the progestin metabolism
of the pregnant mare and fetus during later gestation.in addition, the
early equine embryo will be examined regarding its steroid production,
as well as presence of the plasminogen activator.With GC/MS
techniques, definitive identification and specific monitoring of the
steroids is possible.Finally, the biological actions of some of the
progestins will be monitored in cycling mares.34
XPERINT 1
P#
MATERIALS AND METHODS
T OF AT-GESTATION
MARE AND FETUS
1. Purpose
As indicated in the literature review, a number of progestin
compounds have been identified in the pregnant mare during the later
stages of gestation.Only one study (Holtan et al.,1991) indicated
actual concentrations and identification of these progestins. Therefore,
in this experiment, cannulae were placed into fetal and maternal vessels
of late-gestation mares in order to confirm the identity and amounts of
the following plasma progestins: 5a-pregnane-3,20-dione (5a-DHP), 4-
pregnene-3,20-dione(P4),313-hydroxy-5-pregnen-20-one(P5),3p-
hydroxy-5a-pregnan-20-one(3I3-5P),20a-hydroxy-5a-pregnan-3-one
(20a-5P),5-pregnene-313,20(3-diol(P5-1313),5a-pregnane-313,2013-diol
(pp-dion, and 5a-pregnane-313,20a-diol (pa-diol). With cannulations of
the vessels, collection of samples over time was attempted.
2. Animal Protocol
In this study, as well as all of the following experiments, the
animals used were mature pony mares. All were maintained in the same
outdoor environment on a standard grass hay and grain diet.From this
research herd, six pregnant pony mares were chosen for the cannulation
experiment. The gestational ages of the mares were: 4446 (290 d), 4448
(299 d), *59 (285 d), *75 (313 d), *76 (160 d) and 4481 (313 d).35
Prior to the surgeries, four cannulae were prepared for each of
the six mares. For ease of insertion and flexibility, the cannulae were
comprised of two types. The entire cannula was approximately 1.2 m in
length, with .3 m of small diameter (.040 mm o.d. X .025 mm i.d.) Micro-
Renathane (Braintree Scientific, Braintree, MA) tubing bonded with
Silastic Medical Adhesive (Dow Corning Corporation, Midland, MI) to .9 m
of larger diameter (.040 mm i.d. X .085 mm o.d.) Silastic tubing (Dow
Corning Corporation).The four cannulae were bevelled on the end of
insertion, and marked at measured intervals which allowed the surgeon
to monitor the length inserted into each vessel.The opposite end was
color coded such that each vessel could be identified externally.The
cannulae were flushed three times with TDMAC-Heparinizing solution
(Braintree Scientific), which coated the inside of the tubing to help
prevent clot formation and subsequent blockage. The cannulae were then
dried with N2, packaged, and sterilized with Anprolene gas.
Mares were maintained under general anaesthesia with artificial
ventilation for the cannulation procedure, which required approximately
3 to 6 h in a standard surgical setting (Com line et al., 1975; and Silver,
1980).An incision was made, and the cannulae were placed into four
vessels: uterine or maternal artery, uterine vein, fetal artery, and fetal
vein.In the first two mares, lateral abdominal incisions were made.
However, due to problems with herniations at the suture line after
surgery, mid-ventral abdominal incisions were used in subsequent
surgeries.
Once all cannulae were situated and determined to be patent, they
were extruded from the body via a puncture in the upper flank region.
Since the fetal vessels, especially the fetal artery, were more prone to36
blockage due to clot formation, a continuous flush device (IntrafloII
with filter, Abbot-Sorenson, Santa Fe Springs, CA) was filled with
dilute sterile 5 Wm] heparinized saline (Kendall McCaw Laboratories,
Irvine, CA), and attached externally to the cannula.
The mares recovered from surgical anaesthesia and were standing
within a few hours. Banamine (200 mg, Scheming, Kenilworth, N.J.) and
antibiotics (Genocin 400 mg and Penicillin 4X106 IU, both from Pfizer,
New York, N.Y.) were administered i.m. twice daily for six days following
the surgery.Fetal well being was monitored via trans-abdominal
ultrasound (Aloka 210-DX with 5-MHz probe, Corometrics Medical
Systems Inc., Wallingford, CT) twice daily, as well as packed cell
volume (PCV) on the fetal samples. Temperature, pulse, and respiration
were closely monitored on the mares.Blood samples, obtained from
each cannula, were collected into heparinized tubes or syringes twice
daily, centrifuged, and the plasma kept at -20 0C until assayed.Each
cannula was flushed with a dilute sterile 5 IU/m1 heparinized saline
solution, and left filled with a more concentrated 200 IU/mlheparinized
saline solution.
3. Assay Protocol
a. Progestln Standards
All plasma samples were analyzed with GC/MS procedures, using a
protocol similar to that described by Holtan et al. (1991). Progestin
standards were: 5a-DHP, P4,P5, 3I3-5P, 20a-5P, P5-13p, and
Da-diol, which were allobtained from Sigma,St.Louis, MO,or
Steraloids Inc., Wilton, N.H., and used without further purification (see
structures in Figures 1 and 2).37
Deuterium labelled progestins were utilized as internal standards
in the analysis of samples.Deuterium labels were incorporated into
four of the progestins, 5a-DHP, P5, 3I3-5P, and 013-diol, with a protocol
similar to that noted by Dehennin et al. (1980). Both P5 and 3I3-5P were
deuterated by a proton for deuterium exchange to yield [17,21,21,21
2H] -P5 (D4-P5), and [17,21,21,21-21+313-5P (D4-30-5P). Then D4-313-5P
was reduced to form D4-013-diol, or oxidized to form D4-5a-DHP.
Approximately 250 mg of 313-5P, and 250 mg of PS were placed in
separate 150-ml round bottom flasks with 20 ml of deuterated methyl
alcohol, 1 ml of sodium deuteroxide (both from Sigma), and a few boiling
chips.These mixtures were refluxed for 5h,then the solvent
evaporated with N2 at approximately 30 0C.Five millilitersof
deuterated water and 1 ml of deuterated acetic acid (both from Sigma)
were added. The solution was then extracted three times with 20 ml of
anhydrous ethyl ether (Mallinckrodt Specialty Chemical Co., Paris, KY).
The extract was collected into 15-m1 centrifuge tubes and the ether
evaporated with N2.Before recrystallization, each progestin was
checked for deuterium incorporation on the GC/MS using full-scan mode
(increased molecular weight by four). Some of the D4-3I3-5P was then
used to make D4-5a-DHP (oxidation), and D4-I313-diol (reduction)
For the reduction reaction to form D4pp -dioi, approximately 75
mg of D4-3f3-5P were dissolved in 10 ml of deuterated methyl alcohol,
and 200 mg of sodium borohydride (Sigma) added.This solution was
incubated in a water bath at 50 OC for 45 min. The reaction was stopped
with 1 ml deuterated acetic acid.Ten milliliters of deuterated water
were then added, and the mixture transferred to a separatory funnel
where it was extracted with 100 ml of ethyl ether.The extract was38
collected into centrifuge tubes and the ether evaporated with N2.A
small amount was checked on the GC/MS using full scan mode prior to
recrystallization.
Another 75 mg portion of the D4-313-5P was oxidized to form D4-
5a-DHP. The D4-313-5P was dissolved in 2 ml of deuterated acetic acid,
and six drops of a 5% chromium oxide (Sigma) solution added.This
reaction mixture was incubated 1 h at room temperature in the dark, and
stopped by adding 5 ml of deuterated water. It was then extracted three
times with 15 ml of ethyl ether, the extract collected in centrifuge
tubes, and the ether evaporated with N2.The product was checked on
GC/MS full scan mode prior to recrystallization.
All four deuterium labelled progestins were then recrystallized.
To each progestin, 2 ml of deuterated water were added and heated in a
water bath to 80 0C.Deuterated methyl alcohol was added stepwise
until the mixture went into solution.Each was then cooled at room
temperature for 2 h,and placedinthe freezer overnight.The
crystallized yield was filtered over paper under vacuum.Since some
went into the liquor portion, it was ref iltered at least one additional
time. The products were then transferred to aluminum foil, and dried in
a warming oven overnight. At least 30 mg of each were recovered. All
were derivatized and checked for purity onfull-scan mode of the
GC/MS.
A set of stock standards (1 mg/ml) were made by dissolving each
of the eight non-deuterium progestins, and each of the deuterium
labelled standards in methyl alcohol (spectro. grade, Mallinckrodt).
From these 12 concentrated stock solutions, a mixture of the eight non-39
deuterium progestins, and a mixture of the four deuterium labelled
standards at the concentration of 10 Kg/m1 were prepared in methyl
alcohol.
The two mixtures were used to prepare standard sets for each
assay.For each of the eight progestins, standard regression response
lines were developed by adding a constant amount (400 ng) of the
deuterium mix, and varying amounts of the non-deuterium mix (100,
200, 400, and 800 ng) to 5 ml of plasma from an ovariectomized mare.
While P5,5a-DHP, 31i-5P, and 013-diol were all calibrated from their
respective deuterium labelled internal standards, P4 used the 114-5a-
DHP internal standard, 20a-5P used the D4-313-5P, and P5-I313 and Pa-
diol both used the D4-1113-diol internal standard.These calculations
were conveniently done by the GC/MS software program (MS Chem
StationHP 01034B, Hewlett Packard, Kennett Square, PA). The area of
each progestin standard was divided by its appropriate deuterium
internal standard resulting in the response ratios, which were graphed
against the amount ratios. All unknown concentrations in samples were
then calculated from these standard lines.In addition to the standards
in plasma, standard sets were also prepared without plasma in order to
determine extraction efficiencies.
To analyze plasma samples, from 4 to 5 ml of each sample were
pipetted into 20-ml glass scintillation vials, and 400 ng ofthe
deuterium mix internalstandards were added.Allsamples and
standards were extracted and derivatized using the protocols outlined in
the following sections.40
b. Extraction of Steroids
A solid phase extraction was used for the plasma samples and
standards. C18 Sep-Pak Plus cartridges (Waters Associates, Milford,
MA) were activated with 2 ml of methyl alcohol followed by 5 ml of
water. Plasma samples and standards in plasma were placed into 10-ml
plastic syringes and passed through the Sep-Pak dropwise.By slowly
pushing samples through, extraction efficiency was greatly enhanced.
The sample vial was then rinsed with 1ml of water that was also
passed through the Sep-Pak. Then 3 ml of water, and 2 ml of hexane
(HPLC grade, Mallinckrodt) were passed through the Sep-Pak with glass
syringes. The steroids were then eluded from the Sep-Pak with 4 ml of
ethyl ether, which again were passed through gently with a glass
syringe. The extract was collected in 3.7-ml glass screw cap vials with
teflon lined caps (Fisher Scientific, Pittsburgh, PA), and the ether
evaporated with N2 at 45 0C in a Pierce Reacti-Vap Evaporating Unit
(Pierce, Rockford, IL).
c. Derivatization
Derivatizing reagents were added to each sample and standard.
Sixty microliters of a 2% methoxyamine-hydrochloride in pyridine (MOX
reagent, Pierce) solution was pipetted into each vial and vortexed. The
capped vials with MOX reagent were incubated at 60 0C for 30 min in the
evaporating unit. Vials were then uncapped, and the pyridine evaporated
with N2. The MOX reagent derivatized the progestins with oxo-groups to
methoxime.
Inthesecondstepoftheprocedure,TBDMS(ortert-
butyldimethylsily1) derivatized unhindered hydroxyl groups present on41
progestins.Fifty microliters of a 5% solution of diethylamine in
dimethylformamide (both from Pierce), plus 25 p.1of MTBSTFA [N-(tert-
butyldimethylsily1) N- methyltrifluoracetamidel also from Pierce, were
added to each vial, vortexed and incubated at 80 0C for 45 min. To stop
the reaction, .5 ml of water were added and vortexed. Then the samples
were extracted twice with 4 ml of ethyl ether, and the ether evaporated
with N2.It was important to rinse the walls of the vials with a few
drops of ether to concentrate the steroids at the bottom of the vials.
The samples were resuspended in25 p.1of n-undecane (Sigma), warmed
slightly and vortexed.Each sample was transferredto capped
autosampler vials(32mm X11 mm, Hewlett Packard) for GC/MS
analysis.
d. GC/MS Program
The Hewlett Packard 5890 Series II gas chromatograph with an
Alltech fused silica capillary column(30m X.25mm i.d., SE-30,
Alltech, Deerfield, IL) had a temperature program of20OC per min from
1500C to3100C, with total run time of25min per injection.The
Hewlett Packard autosampler injected 1KI of each sample in splitless
mode.Interfaced to the gas chromatograph, was a Hewlett Packard
5971AMass Selective Detector. The full-scan mode (FSM) was used for
identification and qualitative runs, while the selected ion mode (SIM)
was used for quantitative work.The system was controlled by the
computer with the MS Chemstation software, which compared steroid
peak areas to internal standards, and calculated ng/ml amounts from the
response lines created by the standard ratios.42
e. P4 EIA Cross-reactivity
Sample sets from three of the mares cannulated (#46, *48, and
*59) were also analyzed with a commercial P4 EIA kit (Novo Biolabs
Ltd., Cambridge, UK).Since most of the samples tested on this EIA
resulted in maximum levels on the assay standard curve (10 ng/ml P4),
it was suspected that progestins other than P4 were binding to the P4
antibody. Cross-reactivity experiments with the progestins known to be
present in late-gestation mare and fetal samples (5a-DHP, P4, P5, 30-
5P, 20a-5P, P5-130,1313-dio1, and pa-diol) were then undertaken on the P4
kit assay.Each of the progestins were testedat 10, 100, and 1000
ng/ml concentrations in plasma from an estrous mare.
The assay is a competitive EIA technique. A detailed protocol for
the procedure and all reagents needed are included with each 96-well
microtiter plate kit.The microtiter plates are pre-coated with P4
antibody. Aliquots (20 RD of the plasma samples and each standard (1,
2.5, 5, and 10 ng/ml) were added to duplicate wells, and 100 IL1of
conjugate added to each well.The plates were incubated at room
temperature for 20 min.The plates were inverted to remove well
contents, and washed three times with a washing solution.The
substrate and amplifier were pipetted to each well (100 µ1 of each), and
incubated at room temperature for 10 min. The reaction was stopped
with a .3M sulphuric acid solution. Absorbance of standards and samples
were read at 492 nm on a Titertek Multiscan Plus MK11 microelisa
automatic plate reader (Flow Laboratories Inc., Inglewood, CA).43
4. Statistical Analysis
All additional calculations of data and assay statistics, such as
coefficient of variation, recovery percentages (accuracyof added
hormones), sensitivity, and extraction percentages, were done on
Macintosh Excel software (Apple Computer Inc., Cupertino, CA).
Due to problems encountered in the long-term cannulations of the
pregnant mares (herniations, abortions, and blockage of cannulae) over
extended time, samplings were irregular.Consequently, only initial
samplings were used for statistical analysis.A randomized block
design analysis of variance (general linear model or GLM) on SAS (Cary,
N.C.) was used to determine mare (random, block effect) and vessel
(fixed, treatment effect) differences for the eight progestins (dependent
responsevariables).A multiplecomparison(leastsignificant
difference or LSD, with SAS) was also applied to the data setif
significant differences were found to determine where variations
occurred in the data.In addition, multiple paired t-tests were run to
determine differences between each of the eight hormones within each
vessel (SAS).The data was log 10 base transformed due to obvious
unequal variances in hormone levels.
EXPERIMENT 2: PROUSTIN METABOLIC STUDIES UTILIZING
DEUTERIUM PREGNENOLONE INFUSIONS TO FETAL
VESSELS IN LATE-GESTATION MARES
1. Purpose
The differences in concentrations of the progestins between
maternal and fetal vessels indicated in the literature suggest several
metabolic sites. The objectives of this study were to determine, with44
infusions of a labelled precursor steroid (deuterium P5) to the fetal
circulation, and samplings over time, possible sources and metabolic
locations of the various progestin metabolites.The non-ionizing
deuterium label would be easily traced, with GC/MS analysis of plasma
samples, to the subsequent progestins down the metabolic pathway from
P5.
2. Animal Protocol
Two pregnant pony mares at290 d (*46) and 313 d (081)
gestation were cannulated as noted in Experiment 1.After the cannulae
were in place and patent, 10 mg of D4-P5 (prepared as indicated in
Experiment 1) were infused into the fetal arterial cannula.Samplings
from each of the four cannulae were collected at timed intervals (0, 10,
20, 40, 60, 90,120, and160 min) afterinfusion.To prevent
hemorrhagic shock in the fetus, only approximately 2 ml of plasma were
collected at each fetal sampling which necessitated pooling of these
samples prior to analysis.At least 5 mi samples of plasma were
collected from the maternal vessels each time.All plasma samples
were centrifuged and stored at -20 0C until assayed. At the end of the
sampling period, the animals were euthanized.
3. Assay Protocol
a. Standards
In the samples collected in this experiment, the steroids of
interest should be deuterium labelled progestins derived from the
infused D4-P5.Consequently, deuterium labelled progestins could not
act as internal standards, and instead, 4-cholesten-3-one (Steraloids)45
was used. A 10 µg /ml solution of 4-cholesten-3-one in methyl alcohol
was prepared. Using the same principles outlined for Experiment 1, 4-
cholesten-3-one (2000 ng) was added toall plasma samples and
standardsastheinternalstandard,priortoextractionand
derivati zati on.
A standard regression response line was established for each
progestin by adding varying amounts of the progestin mix (100, 200,
.400, and 800 ng), and a constant amount (2000 ng) of 4-cholesten-3-one
to 5 ml of ovariectomized mare plasma.All progestin concentrations
were calculated from the 4-cholesten-3-one.
b. Extraction of Steroids
Due to poor extraction efficiency of 4-cholesten-3-one in plasma
by Sep-Paks, ether extraction was used on all standards and samples in
this experiment.Plasma samples and standards (4 to 5 ml) were
pipetted into 15-m1 glass vials with teflon lined screw caps, and the
internal standard added. Each sample or standard was extracted twice
with 8 ml of ethyl ether. The extract was transferred into 3.7-m1 glass
vials with teflon lined screw caps, the ether evaporated with N2,
derivatized, and analyzed by GC/MS as indicated in Experiment 1.
4. Statistical Analysis
As in the first experiment, Macintosh Excel software was used for
assay statistics. Statistical analysis of the data was completed using
SAS.In general, it appeared that the progestin concentrations were
higher at the 10 min sampling. Therefore, a randomized block design46
was used to compare the eight progestin concentration differences
(dependent response variables), between mares (random, block effect)
and vessels (fixed, treatment effect) at this sampling time, with an
analysis of variance (GLM).A multiple comparison (LSD) was also
applied when concentrations differed to determine the sources of the
variations.Multiplepairedt-testsdetermined whereprogestin
concentration differences existed within each vessel.In addition, since
samplings were collected over time, a split plot repeated measures
analysis of variance using GLM on SAS was used.The model had the
variable of over time effects, in addition to the 10 min sampling design
noted above.The data in this experiment, as in the first experiment,
obviously did not have homogeneous variance, which necessitated log
transformations of the data in all analyses.
EXPERIMENT 3: METABOLIC CAPABILITIES OF FETAL
MATERNAL TISSUES FROM LATE-GESTATION MARES
1. Purpose
Incubation studies have proven to be useful in identifying enzymes
present within specific tissues as was noted in the literature review.
The purpose of this experiment was to identifymetabolic capabilities
of the various fetal and maternal tissues from mares In the later stages
of gestation.By co-incubating the tissues with a labelled progestin
precursor steroid (D4-P5), it would be possible to determine which
progestins each tissue could produce by GC/MS analysisofthe
incubation medium for deuterium labelled steroids derived from D4-P5.47
2. Animal and Tissue Incubation Protocol
Two pregnant pony mares both at 313 d gestation (*75 and *81)
were used in this experiment. Each mare was euthanized and the tissue
samples promptly collected into sterile containers, placed on ice, and
transported to the laboratory forincubations.Tissues collected
included mare uterine endometrium, placenta, fetal gonads (ovaries,
since both foals were fillies), fetal adrenals, fetal liver, and fetal
kidneys.
All equipment used in the incubations was autoclaved.Incubation
medium was Medium199 (M199) with Hank'ssaltsand sodium
bicarbonate (Sigma).It was sterile filtered and endotoxin tested.The
stock solution of M199 was gassed with 95% 02 and 5% CO2 for 20 min.
Five milliliters were pipetted to each of the sterile 25 ml Erlenmeyer
Flasks, and kept at 4 0C. Two 1g samples of each tissue were minced
with scissors, and added to the flasks as duplicates.The flasks were
gassed again briefly, capped with rubber stoppers, and placed in a
shaking water bath at 37 OC for an 1h pre-incubation. Medium blanks
served as control incubations.
After the 1h pre-incubation, the medium was removed and
replaced with new medium. The flasks were again gassed briefly.To
one of the duplicates of each tissue type, 25 Rg of D4-P5 were added.
All flasks were then incubated for 4 h at 37 0C in the shaking water
bath. Medium and tissue were then kept at -20 OC until assayed.48
3. Assay Protocol
a. Standards
As in Experiment 2, the medium samples obtained from the tissue
incubations were being analyzed for deuterium labelled metabolites
from the D4-P5 in the medium. Therefore, 4-cholesten-3-one was used
as the internal standard as indicated in Experiment 2.
b. Extraction of Steroids
The 4-cholesten-3-one in medium extracted efficiently (>90%)
through Sep-Paks, therefore all samples in this experiment were
extracted as indicated in Experiment1.Derivatization and GC/MS
programming was also as noted in Experiment 1.
4. Statistical Analysis
Assay statistics were done with Macintosh Excel. SAS was used
for the data analysis. Randomized block design GLM analysis of variance
determined mare (random, block effect) and tissue (fixed, treatment
effect)differencesfortheprogestinconcentrations(dependent
response variable). Multiples comparison tests (LSD) were applied when
differences occurred.In addition, multiple paired t-tests were done to
determine hormone differences within each tissue.All data was log
transformed due to obvious heterogeneous variance.49
EXPERIMENT 4: STEROID METABOLISM AND THE
T I I0
EARLY EQUINE EMBRYOS
1. Purpose
Metabolic intermediates between the estrogens and progesterone
produced by equine embryos in early gestation have not been identified.
One of the objectives of this study was to identify with GC/MS both
progestins and estrogens produced by the equine embryo during the 14 to
18 d stage.Steroid metabolism may be associated with maternal
recognition of pregnancy, which occurs at this stage of gestation in
mares.In order to trace progestin metabolism by deuterium labelling
with GC/MS, some of the embryos were incubated with varying amounts
of D4-P5.Additionally, since no work has been published regarding
plasminogen activator in the equine embryo, identification of this
protein in the incubation medium and embryonic tissues was included in
the protocol.
2. Animal and Embryo Incubation Protocol
Nine pony mares (*35, *43, *44, *60, *72, *77, *78,4:80, and
*83) were bred to the same pony stallion via artificial insemination.
All mares were teased, palpated rectally, and scanned transrectally
with ultrasound daily to accurately determine readiness for breeding,
day of ovulation, or pregnancy.
All embryos collected were 14 to 18 d after ovulation.After
identifying normal embryos via ultrasound, the embryo was removed
with a transcervical uterine flushing (Squires etal.,1985).The
flushing buffer was sterilized by filtration (Falcon 7105 .22 pm filter,50
Becton Dickinson, Lincoln Park,N.J.),and consisted ofDulbecco's
Phosphate Buffered Saline or PBS (Sigma) at pH=7.2 and 37 0C.All
equipment and tubing used in the embryo collections were sterilized
with gas or steam.
Flushing medium was collected into glass graduated cylinders, the
embryo removed, and examined on a low power microscope to be sure it
was intact. Each embryo was then transferred to a warmed culture dish
(60 X 15 mm, Corning Glassworks, Corning, N.Y.) with 5 ml of the culture
medium (Minimum Essential Medium or MEM, with Hank's salts, L-
glutamine, sodium bicarbonate, 100 U/m1 penicillin G, and 100 µg/m1
streptomyocin, all from Sigma).In five of the embryos cultured, 1%
heat inactivated horse serum (Gibco Lab, Grand Island, N.Y.) was also
added to the culture medium.The other four embryos were used in
plasminogen activator assays which required serum free medium.
Medium was placed in the incubator at 39 0C in a humidified atmosphere
of air in 5% CO2, for 24 h prior to adding the embryo.
Each embryo was rinsed three times in medium, and then pre-
incubated for 2 h. After the pre-incubation, the embryo was transferred
to a new dish with medium, and incubated 24 h.Control medium blanks
were also included with each incubation.In the culture of three
embryos, varying levels of D4-P5 were added to the 24 h incubation
medium (2500, 5000 and 20,000 ng).After the 24 h incubation, the
embryo and medium were stored at -20 OC until assayed.51
3. Assay Protocols and Statistical Analysis
a. Steroid Assay Protocol
GC/MS progestin analysis ofthe medium from the embryo
incubations was Identical to the protocol for tissue Incubations noted
for Experiment 3.In addition to the progestins, an androgen and
estrogens (see structures in Figure 3) were studied In these embryo
samples.
Stock standards of 1 mg/ml were prepared of 4-androstene-3,17-
di one (androstened i one, AND), 3-hydroxy- 1 ,3,5( 1 0)-estratri en- 1 7-one
(estrone,E ),1 ,3,5( 1 0)-estratriene-3, 1 713-diol(estradiol,E2),and
1,3,5(1 0)-estratriene-3,16a,170-triol (estriol, E3). A mixture of these
four steroids at a concentration of 10 p.g /ml in methyl alcohol was then
prepared.Standard regression lines against 4-cholesten-3-one were
developed for each hormone as was outlined for the progestins in
Experiment 1. These four steroids were identified and quantified in five
of the embryos collected.
ExtractionofmediumwasaccomplishedwithSep-Paks.
Derivatization and GC/MS programs did not differ from techniques
discussed in Experiment 1.Assay statistics were done on Macintosh
Excel.Statistically, the deuterium progestin concentrations and the
various treatment levels were analyzed in a regression using SAS to
deterimine if there was a relationship between amount of D4-P5, and
the metabolites formed. The estrogen data was analyzed as a one way
analysis of variance (GLM) on SAS, with a multiple comparison test
(LSD) to determine where differences existed between hormones.52
b. Plasminogen Activator Assay Protocol
The embryo medium samples were concentrated from 2 ml to 50
R1 in Amicon Centricon Microconcentrators (Amicon, Danvers, MA) which
were centrifuged for approximately 10 min.To each concentrated
medium sample, 50 p.1of sample buffer was added (5.0% SDS, 20%
glycerol, .0025% bromophenol blue, all in .125 M Tris HC1 buffer, all
supplies from Sigma).The embryo tissues were placed in 500 RI of
sample buffer overnight at room temperature. The following day, each
was vortexed, centrifuged to settle the tissue, and the supernatent then
drawn off for the assay.
A SDS polyacrylamide gel electrophoresis assay was used to
characterize plasminogen activatorinthe medium and embryonic
tissues of four embryos collected. A standard protocol for SDS PAGE
was used for this experiment (Bio Rad., 1987).One lane on each gel
contained the following Bio Rad protein standards:rabbit muscle
phosphorylase b (97.4 KD), bovine serum albumin (66.2 KD), hen egg
white ovalbumin (45.0 KD), bovine carbonic anhydrase (31.0 KD), soybean
trypsin inhibitor (21.5 KD), and hen egg white lysozyme (14.4 KD). Two
other lanes were used for tissue type plasminogen activator standard
(tPA) at 10 ng/ml, and urokinase type plasminogen activator standard
(uPA) at .1IU /ml (Sigma).Sample or standard (100 R1) was added to
each well in a 4% stacking gel with 12% separating gel. Electrophoresis
was conducted through the stacking gel at 20 mA, and 30 mA through the
separating gel over approximately 3 h.After electrophoresis was
complete, the gels were placed in 2.5% Triton X-100 (Sigma) in water,
and shaken gently for 30 min, followed by a rinse in PBS.53
At this time, a casein-agar zymograph was prepared (Granelli-
Piperno and Reich, 1978; Vassal li et al., 1984).Four grams of nonfat
dry milk (Carnation Co., Los Angeles, CA) was dissolved in 100 ml of
buffer containing .0013 M CaC12-2H20, .1 M glycine, .038 M Tris, and .005
M sodium azide (all from Sigma). Seven milliliters of the milk mixture
at 55 0C was added to 7 ml of a 2% agarose (Sigma) in water at 55 0C.
Purified human plasminogen was added to the milk-agarose solution to
make a 30 Rg/m1 solution.Ten milliliters of this mixture was
transferred to a 13 X 8 cm glass plate, and allowed to gel for 10 to 15
min. In addition, zymographs without human plasminogen were prepared
for the detection of any nonspecific proteolytic activity.
A gel "sandwich" was then prepared with the acrylamide gel and
the casien-agar zymograph which was wrapped in plastic wrap and
incubated at 39 0C for 24 h. The gels were separated, and the zymograph
fixed with 3% acetic acid for 10 min, and rinsed with tap water.
Zymographs were dried and stained overnight with .05% Coomassie
Brilliant Blue (Bio Rad) in a ratio of water/isopropanol/acetic acid of
65/25/10.
An additional assay was conducted using amiloride zymographs
(Erickson et al., 1984). To prepare this zymograph, a 50:50 solution of
4% nonfat dry milk in buffer with 2% agarose in water was prepared.
Two 9 ml aliquots of this mixture were combined with either 1 ml of
100 mM amiloride (Sigma) dissolved in PBS or a control blank of 1ml
PBS.The plasminogen was added to the mixture as indicated in the
previous protocol, and tranferred to a 13 X 8 cm glass plate.
Protein migration was deterimined by measuring the distance
(cm) from the edge of the separating gel to the center of the lytic zone,54
after fixing the gel.From the distances measured for the set of
standard proteins, a linear regression line was constructed for each
assay on Macintosh Cricket Graph. Each distance (cm) was divided by the
total distance and plotted against the log of the molecular weights
(MW). From the equation generated, the mass of the unknown could be
calculated.
EXPERIMENT 5: THE BIOLOGICAL ACTIVITY OF EXOGENOUS
PROGESTINS IN CYCLIC MARES
1. Purpose
The biological effects of the progestins, other than progesterone,
have not been investigatedinthe mare.The objective ofthis
experiment was to examine the biological action of two progestins (5a-
DHP and 3D-5P) in the nonpregnant mare. Control of gonadotropin (eLH),
behavioral estrus, and ovulation were the parameters studied.
2. Animal Protocol
Twenty-seven estrous cycles, during the natural physiological
breeding season, in eleven nonpregnant pony mares (*44, *57 *59, *60,
*70, *71, *72, *73, *74, *75, and *78) were analyzed in this study.
The mares were teased daily with a stallion to detect estrous behavior.
Each mare was rectallypalpatedand scanned withultrasound
transrectally to monitor ovarian changes daily during estrus and every
other day during diestrus.Blood sampling was also done daily during
estrus and every other day during dietrus.Jugular vein blood was
collected into heparinized tubes, centrifuged, and kept at -20 0C until
assayed.55
Thetreatmentregimeincludedprogestininjections(i.m.)
beginning at 6 d postovulation, and continuing for 12 d or until the mare
returned to estrus.At 8 d postovulation, 5 mg of PGF2a (Lutalyse,
Upjohn Co., Kalamazoo, MI), was administered to regress the corpus
luteum (CL).Lysis of the CL following PGF2a injection was verified
with the P4 EIA (Novo Biolabs).
The progestins tested in this study (P4,5a-DHP, and 313-5P, all
from Sigma), were dissolved in safflower cooking oil at a concentration
of 5 mg/ml, and injectedi.m.Mares were randomly chosen for
treatments, with some mares used for up to three cycles.However, at
least one cycle elapsed between treated cycles.In preliminary work,
three daily dosage levels of 5a-DHP were assessed (10, 25, and 50 mg).
Two mares were injected at each level, and it was determined that 50
mg may be the effective dose.Therefore, in the progestin treatment
group, an additional seven mare cycles were used to further test 5a-DHP
at the dosage level of 50 mg/ml.In addition, four mares were injected
with 50 mg of 30-5P, and two mares with 50 mg of P4.Controls
included two untreated mares, as well as six mares treated with PGF2a
only.
3. Assay Protocol
A non-competitive "sandwich" EIA was developed to analyze eLH
levels in the plasma samples (Wilson et al., 1990).Ninety-six-well
polystyrene square-bottom Immulon-4 microtiter plates (Dynatech,
Chantilly, VA) were coated with 200 µl /well of the capture antibody
(Clone 51857-0220, antibody produced against the 13-subunit of bovine
LH at Monoclonal Antibodies, Mountain View, CA) at a concentration of56
10 vg/m1 in .01 M PBS at pH=7.0. Plates were covered with plate sealers
(Flow Laboratories Inc., Inglewood, CA), and incubated overnight at room
temperature. The following day, the plates were inverted to remove the
antibody, and washed three times with EIA wash buffer comprised of
.04% polyoxyethylene-sorbital monolaurate (Tween 20) and .15 M sodium
chloride (both from Sigma) in distilled water. Plates were inverted and
dessicated in a vacuum overnight at room temperature, and the assay
started the following morning.
Unknowns and standards were tested in duplicate wells (200
µl /well).The eLH standards (based on NIH standard LH-S1, obtained
from Sigma) were at concentrations of 0, 2, 4, 8, 16, 32, 64, and 128
ng/ml. The standards for each assay were diluted in .01 M PBS with
.04% Tween 20, pH=7.0.Standards diluted in plasma resulted in a
similar standard curve (r2=.99), consequently buffer diluent could be
used for the assays. After all samples and unknowns were added to the
wells, the plate was covered with a sealer and incubated at room
temperature for 2 h.Appropriate controls were included on each plate
to monitor non-specific binding.
After incubation, plates were inverted and washed three times
with EIA wash buffer.A second antibody conjugated to alkaline
phosphatase (759610-AP, antibody produced against the a-subunit of
eCG and conjugated to alkaline phosphatase, Monoclonal Antibodies,
Mountain View, CA), was added (200 p.l) at the dilution of 1:300 in
conjugate buffer (42 mM Trizma Base, 50 mM sodium chloride, 15 mM
sucrose,.5 mM magnesium chloride,.1mM zincchloride,.01%
Thimerosal, 1% bovine serum albumin, and .13% Tween 20, at pH=7.0; all57
from Sigma). The plates were covered with sealers, and incubated 2 h at
room temperature.After incubation, plates were inverted and washed
three times with EIA wash buffer.Since the substrate (p-Nitrophenyl
Phosphate, pNPP, Sigma) is light sensitive, it was prepared just prior to
use. A 1 mg/m1 solution of pNPP was prepared in a 1M diethanolamine
buffer with .5 mM magnesium chloride and .01% sodium azide (all from
Sigma) at pH=9.8. The substrate was added (150 Rl/well), covered with
a sealer, and incubated in the dark for 30 min. The reaction was stopped
with 50 µl /well of 50 mM tetra-sodium ethylenediamine tetra-acetic
acid (Sigma), pH=12.5.
The optical densities were read at 405 nm on a Titertek Multiscan
Plus MKII microelisa automatic plate reader (Flow Laboratories), with
programming which calculated a standard curve from the eLH standards
in each assay from which the concentrations (ng/ml) were calculated. A
Titertek multichannel pipette (Flow Laboratories) was used for all
pipetting across the plates.
4. Statistical Analysis
Several one way analyses of variance tests were conducted using
Stat Graphics (STSCInc.,Rockville, MD) to determine differences
between treatment groups (progestin treated, untreated mares, and
PGF2a controls) for both the number of days from the initiation of
treatment to ovulation, and the eLH concentrations on the day of
ovulation subsequent to the treatment.a) 3D-hgdroxy-5-pregnen-20-one (pregnenolone or P5)
H
c) 5a-pregnene-3,20 -dlone (5a-DHP)
b) 4-pregnene-3,20-dtone (progesterone or P4)
H
d) 30-hgdroxg-50.-pregnen-20-one (30-5P)
FIGURE I: Progestin structures a) P5. b) P4, c) Sa -DHP, & d) 30-5P. Systematicnames
& some common names are indicated with each structure. Dashed lines in
LA
structures indicate a -configuration (below the plane). Solid lines indicate B- 00
configuration (above the plane)H
a) 20a-hgdroxy-5(4-pregnan-3-one (206L-51')
--OH
Oh
OO OH
H
c) 50.-pregnans-38,20a-diol (Ba -dial)
b) 5-pregnene-38,208-dial (P5-88)
H
d) 5(4-pragnane-38,20B-dial (88-dial)
FIGURE 2: Prog_estin structures a) 20a -5P, b) P5-BB. c) Ba -diol, & d) BB-diol.
Systematic names are indicated with each structure. Dashed lines in structuresvi
indicate a -configuration (below the plane). Solid lines indicate B-configuration
(above the plane)a) 4-ondrostone-3,17-dfono (ondrootonedfons or AND)
c) 1.3.5 (10)-ostrotrIono -3,1711-dtol (ostredtol or E2)
b) 3-hydroxy-1.3,5 (10)-ootratrion-17-ono (distrait' or El)
OH
d) 1,3.5 (10)-estrotriono-3.160.178-trIol (estrIol or E3)
FIGURE 3: Estrogen and androgen structures a) AND, b) El, c) E2 & d) E3. Systematic
names & common names are indicated with each structure. Dashed lines in
structures indicate a -configuration (below the plane). Solid lines indicate
B-configuration (above the plane).61
RESULTS
ASSAY RESULTS
1. GC/MS
Tables l and 2 contain the full systematic and abbreviated names,
GC/MS retention times, and major ions monitored for the progestins and
estrogens. Figure 4 is a total ion chromatogram on FSM of the progestin
standards with deuterium labelled progestin internal standards, showing
the individual peaks and retention times.These relative retention
times, noted in Figure 4 (see caption), were consistent for all assays.
The deuterium labelled progestins have retention times slightly before
the unlabelled progestins. The doublet peaks observed for both 5a-DHP
and 20a-5P are due to syn- and anti-isomers of methoxime at the
carbonyl group of the third carbon.
Figures 5 through 8 show the individualfull-scans, without
background subtraction,of each progestin and deuteriumlabelled
internal standard of the standard mix in the total ion chromatogram of
Figure 4. Figure 5a shows the full-scan for D4-5a-DHP, of which both
5a-DHP (Figure 5b) and P4 (Figure Sc) were quantified against. In Figure
6a, the full-scan of D4-P5 is indicated.P5, which is quantified with
D4-P5, isin Figure 6b.D4-313-5P (Figure 7a) was used for the
quantification of both 313-5P (Figure 7b) and 20a-5P (Figure 7c).All
three diols, P5-1313 (Figure 8b), (313-diol (Figure 8c), and pa-diol (Figure
8d) were quantified with D4-13p-diol (Figure 8a).
The method of quantification was described in the Materials and
Methods section. The ions monitored for this quanitification on GC/MS62
are noted in Table 1,and can be noted for each progestin on the full-
scans.For progestins with deuterium labels, these ions have masses
which are four units greater than unlabelled progestins. The major ion
is the intact molecular ion (Figure 5c), or more commonly the molecular
ion with a derivative group removed (all other progestins shown). With
the M0 /TBDI15 derivatization, compounds with keto-groups have 29
added to their molecular weights for every keto-group present, while
compounds with unhindered hydroxyl-groups have 114 added to their
molecular weights for each hydroxyl group.Hybrid compounds with a
keto- anda hydroxyl-group would have 114 and 29 added to their
molecular weight. The keto-derivatives remove 31from the total
weight, while hydroxyl-derivatives remove 57 when fragmented.
In addition to the major ions monitored, other ions appear
consistently, since each progestin breaks down in a predictable pattern
of fragments.The progestins with 20-position keto-groups (Figures
5a,b,c, 6a,b, and 7a,b) have in addition to the major ion, a fragment with
a mass of 100, or if deuterium labelled, a mass of 104. This fragment
includes the 20-position derivative plus a portion of the D-ring of these
compounds. When the compound has a hydroxyl-group at the 20-position
(Figures 7c, and 8a,b,c,d), characteristic 103 and 159 mass ions, or 106
and 162 if deuterium labelled, appear on the scan.For identification
purposes, these distinctive "fingerprints" allow definitive identification
of unknown compounds.
The total ion chromatogram for the estrogen standards with 4-
cholesten-3-one is shown in Figure 9a. Figure 9b is an individual full-
scan of 4-cholesten-3-one, the internal standard used for the estrogen
quantification since no deuterium labelling was feasible without the63
21-carbon progestin structure. This internal standard was also used in
the detection of deuterium labelled progestin metabolites.Figure
10a,b,c,d are individual scans of androstenedione and the estrogens
(without background subtraction), showing the major ions monitored as
well as the various fragments characteristic for each compound.The
ion monitored was the intact molecular ion (Figure10a), or the
molecular ion with a single derivative group removed (Figure 10b and c).
A major fragment was also used for the monitored ion (Figure 10d).
Representative standard curves are shown for a dione progestin
(Figure 11a), a mono-hydroxy progestin (Figure11 b),a di-hydroxy
progestin (Figure 12a), and an estrogen (Figure 12b).The standard
curves varied due to differencesin the response of the various
progestins relative to their actual amounts in the GC/MS system.
Since internal standards were used in all assays, extraction
efficiencies were not crucial.However, extraction efficiencies were
calculated for each of the extraction techniques used and found to vary
from 71% to 78% for plasma, and 94% to 97% for medium samples.
Overall assay sensitivity,as determined by adding two standard
deviation units to the lowest detectable reading, was usually at least
.64 ng/ml.
All assay performance information from Experiment 1, for each
progestin in plasma (Sep-Pak extracted), is listed in Table 3.Assay
performancefor Experiment2,forplasma samples withether
extraction, is noted in Table 4.In both Experiments 3 and 4, medium
samples were extracted with Sep-Pak.Assay performance for the
progestins analyzed In these experiments are in Table 5.in Experiment
4, estrogens were also analyzed. Assay performance is noted in Table 664
for the estrogens studied in Experiment 4. The recovery % refers to the
amount of a steroid measured with the assay compared to the actual
amount added.In most cases, it was near 100%, but did range from
72.9% to 110.7%. The recoveries were determined with standards added
to plasma at four concentrations and averaged over several assays (see
notes on Tables 3 to6).The coefficient of variation was also
determined with standards added to plasma at four concentrations and
tested within assays (intra assay %) as well as between (inter assay %)
several assays (see notes on Tables 3 to 6).Intra assay % ranged from
4.0 to 15.3%, while inter assay % ranged from 4.1% to 23.3%.
Full-scans on GC/MS provide a definite identification of steroids
as seen with the standards discussed previously in this section. Some
examples of actual samples, which will be discussed in greater detail in
the subsequent sections, are shown in Figures 13 to 17.In Figure 13a, a
total ion chromatogram is shown for a fetal artery sample in Experiment
1.The large peak at 11.6 is P5 (full-scan in Figure 13b) and the small
peak at11.8is31i-5P(Figure13c).Figure14a,b,c,dareion
chromatograms from an uterine vein sample after infusion of D4-P5 into
the fetal artery. The GC/MS allows detection and identification of the
deuterium labelled metabolites. In Figure 14a, the two compounds with
the 404 ion are shown (30-5P and 20a-5P), while their corresponding
deuterium labelled metabolites with the 408 ion are seen in Figure 14b.
Additionally, both labelled (ion 495 in Figure 14d) and unlabelled (ion
491 in Figure 14c) 13a-diol can be detected.
Some of the deuterium labelled metabolites produced in the tissue
incubations are shown in Figure 15. D4-P4 was produced in endometrium
(Figure 15a) and placenta (Figure 15b).D4-P5-1313 was produced by fetal65
liver (Figure 15c).Evidence of the production of deuterium labelled
metabolites was also shown by embryos (Figure 16). A full-scan of the
precursor added is shown (D4-PS in Figure 16c). Two metabolites are
shown, D4-P4 (Figure 16b) and D4-30-5P (Figure 16d).In Figure 17,
evidence for the identification of P4 (Figure 17a), El (Figure 17b), and
E2 (Figure 17c) in embryos is given.
2. SDS PAGE
A typical standard curve for the plasminogen activator SDS PAGE
assay is depicted in Figure 18a.Molecular masses were determined
from this curve as indicated in the Materials and Methods section.
3. Equine LH EIA
The intra-assay coefficient of variation was 8.3%, while the
inter-assay coefficient of variation was 1 1.6 %, which were determined
from seven different concentration levels of eLH.Assay sensitivity,
determined by adding two standard deviations to the 0 reading, was
estimated to be .97 ng/ml. A typical standard curve for this assay is
shown in Figure 18b.
In addition, the eLH EIA assay protocol was effectively used to
determine equine chorionic gonadotropin (eCG) concentrations in plasma
samples from pregnant mares in a sample set collected in an earlier
study.Due to the structural similarities between eLH and eCG, both
hormones will bind to the same antibodies.66
EXPERIMENT 1: PROGESTINS OF THE LATE GESTATION
MARE AND FETUS
1.Progestin Concentrations Determined with GC/MS
The mean concentrations for each of the progestins (plus or minus
standard error), in the uterine or maternal artery, uterine vein, fetal
artery, and fetal vein were calculated for the six cannulated mares
(Figures 19 and 20). There were no significant differences between the
mares for all of the progestins except P4 and 20a-5P, which were
different between mares (P < .05).Multiple comparison tests revealed
thatthe mares differing fromtheothersforP4 and 20a-5P
concentrations were *75, *76, and *81.
Mare *76 had higher (P < .05) average P4 levels for the four
vessels (12.8 ng/ml) than the other mares, due to her earlier stage of
pregnancy (160 d). The differences for 20a-5P were due to both mares
*75 and *81, who had average levels of 909.5 and 651.0 ng/ml
respectively, which were higher (P < .05) than the other mares.This
variation was due to *75 and *81 being at a slightly later stage of
pregnancy (313 d). Mare *76, at a much earlier stage of pregnancy (160
d), had (P < .05) lower 20a-5P levels (83.5 ng/ml) than the other mares.
The progestin concentrations between thefour vesselsall
differed (P < .05). The predominant progestin (P < .05) in the fetal vein
(Figure 20b) was 5a-DHP (mean of 216.4 +/- S.E. of 24.4 ng/ml). P4 was
also highest (P < .05) in the fetal vein (15.5 +/- 2.8 ng/ml), with lower
levels in the fetal artery (7.8 +/- 5.1 ng/ml), and negligible amounts in
the maternal vessels.In the fetal artery (Figure 20a), P5 (630.8 +/-
298.5 ng/ml), 3I3-5P (117.9 +/- 17.0 ng/ml), P51313 (131.4 +/- 51.8
ng/ml),and IV -diol(32.3+/-12.8 ng/ml) wereallhigherin67
concentration (P < .05) than in the other vessels.The uterine vein
(Figure 19b) had the highest concentration (P < .05) of both 20a-5P
(767.6 +/- 217.9 ng/ml) and as -diol (202.2 +/- 44.5 ng/ml), with the
maternal artery (Figure 19a) having these two hormones predominating
(P < .05), but at somewhat lower levels (20a-5P at 533.2 +/- 201.8
ng/ml and 13a -dial at 150.1 +/- 28.5 ng/ml).
Within each vessel, some of the hormones differed significantly
from the others.In the fetal artery (Figure 20a), P5 (630.8 +1- 298.5
ng/ml) was greater (P < .05) than both 30-5P (117.9 +/- 17.0 ng/ml) and
P5-1313 (131.4 +/- 51.8 ng/ml). The latter two hormones exceeded iv-
diol (32.3 +/- 12.8 ng/ml) in concentration (P < .05).All of these
hormones were greater in concentration (P < .05) than the remaining four
hormones which were all less than 18 ng/ml.
The mean level of 5a-DHP (216.4 +/- 24.4 ng/ml) in the fetal vein
(Figure 20b) was greater than the other hormones at that vessel (P <
.05). Levels of P5 (92.6 +/- 33.7 ng/ml), 20a-5P (57.2 +/- 36.5 ng/ml),
and 313 -5P (41.5 +/- 4.7 ng/ml) did not differ significantly from each
other, but did exceed the remaining four steroids (P < .05), which were
all less than 15 ng/ml.
At the maternal artery (Figure 19a), 20a-5P (533.3 +/- 201.8
ng/ml) was greater than all other hormones (P < .05). The f3a-diol (150.1
+/- 28.5 ng/ml) exceeded the remaining six hormones (P < .05). Both 5a-
DHP (41.3 +/- 10.7 ng/ml) and 3I3-5P (28.2 +/- 3.2 ng/ml) were not
significantly different, but were greater (P < .05) than the other four
hormones (which were all less than 3 ng/ml).
With the uterine vein samples (Figure 19b), 20a-5P (767.6 +/-
217.9 ng/ml) was the highest in concentration (P < .05), with I3a-diol68
(202.2 +/- 44.5 ng/ml) being the second in concentration level (P < .05).
The 5a-DHP (66.4+/- 12.4 ng/ml) exceeded the remaining five hormones
(P < .05), with 3I3-5P (20.3 +/- 2.8 ng/ml) being greater (P < .05) than
the last four hormones which all were less than 3 ng/ml.
2. P4 EIA Cross-reactivity Studies
Samples from both maternal and fetal vessels in mares *59, *48,
and #46 were tested on the commercially available P4 EIA kit, and found
to produce a mean maximal reading of 10.84 +/- 0.34 ng/ml. Since some
of the samples came from maternal vessels, which would normally have
very low levels of P4 according to results published previously (Holtan
et al., 1991), the eight steroids analyzed on GC/MS were tested on the
EIA kit for cross reactivity with the P4 antibody.At the 1000 ng/ml
level, all eight steroids recorded "positive" readings for P4, according to
the kit manufacturer's biologically positive level of 2.5 ng/ml, which
was also at 50% inhibition on the P4 standard curve.The 100 ng/ml
level resulted in readings of over 2.5 ng/ml for 5a-DHP, P4, P5, and 3p-
5P.At 10 ng/ml, only 5a-DHP and P4 were above 2.5 ng/ml.The
concentrations at which each progestin reached the 50% inhibition
capacity (2.5 ng/ml) or greater on the standard curve for the P4 assay
are noted in Table 7.This implies that these hormones were able to
competitively inhibit the binding of P4 to the P4 antibody in this assay.69
EXPERIMENT 2: PROGESTIN METABOLIC STUDIES
UTILIZING DEUTERIUM PREGNENOLONE INFUSIONS
TO FETAL VESSELS IN LATEGESTATION MARES
After the infusion of D4-P5 into the fetal artery, plasma samples
from both fetal and maternal vessels were collected over time in order
to trace the deuteriumlabelled metabolites derived from D4-P5.
Metabolite identification is shown in Figure 14.The data accumulated
in this experiment were multiple readings of the concentrations of eight
progestins over a time period following the infusion. The sites included
the fetal artery and vein, as well as a maternal artery and uterine vein
from the two mares.In sampling from the fetal vessels, less blood
volume was collected at each sampling to avoid hemorrhagic stress to
the fetus.Consequently, for GC/MS analysis it was necessary to pool
some of the samplings to attain adequate volumes resulting in fewer
time readings in the fetal vessels compared to maternal vessels.
The D4-P5 metabolite concentrations over the sampling time
period for the two mares are presented in Figures 21 and 22.There
were differences (P < .05) for all hormones in the various vessels, as
well as over time differences (P < .05) for each hormone.In addition,
there were differences (P < .05) between some vessels over time for
D4-P5 (infused precursor), D4-5a-DHP, D4-P4, D4-313-5P, D4-20a-5P,
and D4-3a-diol.This variation was due to differences of the fetal
vessels and maternal vessels, with D4-313-5P, D4-P4, and D4-5a-DHP
being higher (P < .05) in fetal vessels, and D4-20a-5P, and D4-13a-diol
higher in maternal circulation.
It was also observed from the data, that maximum concentrations
of all hormones were noted at the ten minute sampling in the maternal70
vessels and fetal artery (Figures 21 & 22).Even though the maximum
reading for the fetal vein seemed to occur somewhat later than in the
other vessels,datafromthe10min sampling wereanalyzed
statistically.In statistical analysis of this data set, there were
differences (P < .05) between vessels for D4-P4, D4-20a-5P, D4-313-5P,
and D4-13a-diol, with D4-P4 and D4-313-5P higher in the fetal circulation,
and D4-20a-5P and D4-11a-diol higher in maternal vessels (Figure 23).
In comparing the levels of each deuterium labelled hormone within the
four vessels it was revealed that the predominating progestins were D4-
20a-5P and D4-313-5P. Some hormones, in particular D4-5a-DHP, D4-
P4, and the diols, were at very low levels.
EXPERIMENT 3: METABOLIC CAPABILITIES OF FETAL
MATERNAL TISSUES FROM LATEGESTATION MARES.
The mean concentrations of D4-P5 metabolites for each of the six
tissues were determined (Figures 24 to 26). There were differences (P
< .05) between the tissues for D4-5a-DHP, D4-P4, D4-313-5P, D4-P5-013,
and D4-13a-diol.
Fetal ovary (Figure 24a), mare uterine endometrium (Figure 26b),
and placental tissues (Figure 26a) produced more (P < .05) D4 -5a -DHP
than the remaining tissues. Placental tissue (Figure 26a) produced more
< .05) D4 -P4 than all other tissues.However, all other tissues
incubated produced some D4-P4. The concentration of D4-313-5P was
higher (P < .05) for the fetal ovary (Figure 24a), adrenal (Figure 24b),
liver (Figure 25a), and mare uterine endometrium (Figure 26b). Although
D4-20a-5P was made in the fetal ovaries (Figure 24a), adrenals (Figure
24b), liver (Figure 25a), and mare uterus (Figure 26b), the differences71
were not significant. More (P < .05) D4-P5-130 was produced by the fetal
liver (Figure 25a) than the other tissues.Maternal uterine tissue
(Figure 26b) produced more of both D4-03-diol and D4-13a-diol (P < .05)
than the other tissues. Metabolite identification is shown in Figure 15.
The order of hormones levels produced at each tissue was also
determined. In each tissue, D4-P5 and D4-P4 predominated, with various
other hormones being produced at lower amounts as mentioned in the
preceding paragraphs.In the duplicate incubations of each tissue
without D4-P5, most of the progestins were identified in each tissue.It
was not possible to ascertain whether they were actually metabolized
or merely leaching out of the tissue.
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EARLY EQUINE EMBRYOS
1. Steroid Production
The predominant progestin (P < .05) in incubation medium of
untreated embryos was P4 (Figure 27a).All other progestins tested for
appeared in the incubation medium also, but at lower concentrations.In
the incubation medium of embryos treated with D4-P5 (Figures 27b and
28a,b), the metabolite from D4-P5 produced in the highest amounts was
D4-P4. There was a direct relationship (r=0.61) between the amount of
D4-P5 added to the medium, and the level of D4-P4 produced. The other
deuterium labelled progestins were also produced by the embryos
incubated with D4-P5, but at lower levels than D4-P4.They were
identified with GC/MS full-scan (Figure16).72
Five embryos were also analyzed for estrogens.There were no
significant differences between the embryos for each hormone.The
mean concentrations of the four hormones analyzed (Figure 29) were
different (P < .05).Estradiol (420.9 +/- 95.1 ng/ml incubation medium)
was greater (P < .05) than the other three hormones (estriol 192.9 +/-
57.9 ng/ml, estrone 97.3 +/- 28.7 ng/ml, and androstenedione 34.5 +/-
7.8 ng/ml).Positive identifications of these steroids were possible
with GC/MS full-scans (Figure 17).
2. Plasminogen Activator
The SDS-PAGE assays allowed the identification of plasminogen
activator in both the medium and embryonic tissue samples from four
embryos.Figures 30 to 31 are photographs of some of the dried
zymographs produced. In Figure 30a, lane 1is a medium blank, lanes 2, 3
and 4 are embryo incubation medium samples, lanes 5 and 6 are embryo
tissue samples, and lanes 7 and 8 have urokinase type plasminogen
activator standards, with proteins standards in lane 9. Two weak bands
were observed for the three medium samples at 72.4 KD and 51.3 KD.
The two tissue samples produced four very strong bands at 91.2 KD, 83.2
KD, 72.4 KD, and 51.3 KD.Human urokinase plasminogen activator
standards produced a band at 56.2 KD.Therefore the bands in actual
samples at 51.3 KD are urokinase plasminogen activator.The band at
72.4 KD is tissue plasminogen activator, and the two bands at 83.2 KD
and 91.2 KD are inhibitor complexed to the two plasminogen activators.
Figure 30b has in lane 1a medium blank, lanes 2 and 3 embryo
incubation medium samples, lanes 4 and 5 have diluted embryo tissue
samples, lane 6 is a human urokinase plasminogen activator standard,73
lane 7 is a human tissue type plasminogen activator standard, with
protein standards in lane 8.Medium samples have two weak bands at
53.2 KD (urokinase plasminogen activator)and75.4 KD(tissue
plasminogen activator).Tissue samples have four stronger bands at
53.2 KD, 75.4 KD, 85.9 KD, and 93.7 KD. Again, the two higher KD bands
indicate inhibitor bound to the two types or plasminogen activator.
Human urokinase type plasminogen activator standard has a band at 59.3
KD, while human tissue type plasminogen activator standard has a band
at 69,1KD.No nonspecific proteolytic activity was noted in this
zymograph.
Figure 31 illustrates the results of the amiloride (an inhibitor of
urokinase type plasminogen activator) assay.Lanes 1and 2 have the
human tissue type plasminogen activator and the human urokinase type
plasminogen activator, while lanes 3 and 4 have the two embryo tissue
samples.The gel pictured in Figure 31a had no amiloride added, and
therefore produced results similar to the previous gels.The embryo
tissue samples had bands at 94.3, 87.9, 76.5, and 54.9 KD.Urokinase
plasminogen activator standard was at 61.0 KD, and tissue type
plasminogen activator standard at 67.8 KD.Figure 30b shows the
results from the amiloride zymograph. No bands appeared for the lane 2
urokinase plasminogen activator standard, and the bands at 87.9 and
54.9 KD are absent in the embryo tissue samples, confirming the
presence of urokinase plasminogen activator in these bands.74
EXPERIMENT 5: THE BIOLOGICAL ACTIVITY OF EXOGENOUS
PROGESTINS IN CYCLIC MARES
In the preliminary dosage determining trials, it was noted that
both 10 and 25 mg per day of 5a-DHP were ineffective in inhibiting
estrous behavior or ovulation.All four mares tested at these levels
returned to estrus and ovulated, after receiving a PGF2a injection. The
two mares that were treated with 50 mg of 5a-DHP remained in
diestrusanddidnotovulateuntiltreatmentwaswithdrawn.
Consequently, the 50 mg level was chosen for further studies.
The subsequent testing involved injecting 50 mg of 5a-DHP during
seven more mare cycles. These mares returned to estrus and ovulated
after receiving a PGF2a injection. Four other mares were injected with
50 mg per day of 3I3-5P, which did not inhibit estrus or ovulation either.
Six mare cycles were used as PGF2a controls.These animals all
returned to estrus within 2 to 4 d, and subsequently ovulated within 7 to
12 d. Two mares were injected with 50 mg P4 per day which inhibited
estrus and ovulations until withdrawn.In addition two untreated
control mares were included which had normal 21 d cycles.
In analyzing these data, the 5a-DHP and 30-5P treated animals
were compared to P4 or untreated mares, and PGF2a treated for eLH
concentrations throughout the cycle (Figures 32a,b), eLH concentrations
on the day of ovulation (Figure 33a), and days to ovulations (from d 6
postovulation, Figure 33b).The eLH concentrations were greater (P <
.01) for the 5a-DHP (48.7 +/- 5.1 ng/ml), 3I3-5P (68.1 +/- 7.5 ng/ml),
and PGF2a (67.1 +/- 7.6 ng/ml) groups compared to the P4 and untreated
controls (21.5 +/- 6.5 ng/ml).The eLH for the 5a-DHP, 3I3-5P, and
PGF2a groups were not significantly different.75
Days to ovulation (Figure 33b), from the onset of treatment or d 6
postovulation, in the 5a-DHP group (14.8 +/- 1.2 days) and 30-5P group
(14.2 +/- 0.2 days) were not significantly greater than the PGF2a
control mares (13.3 +/- .4 days). However, these three treatment groups
had fewer days to ovulation (P < .01) than the P4 and untreated mares
(20.8 +/- 1.1 days).TABLE 1: Systematic and abbreviated names. retention times andions monitored on
GC/MS for each of the progestins.
Hormone Systematic Name (Abbreviated name) Retention Time (min)Ion Monitored
5a-pregnane-3,20-di one (Sa -DHP) 11.03 343
11.12 343
4-pregnene-3,20-dione (P4) 11.30 372
3p-hydroxy-5-pregnen-20-one (P5) 12.84 402
3p-hydroxy-5a-pregnan-20-one (3p-5P) 12.98 404
20a-hydroxy-5a-pregnan-3-one (20a-5P) 13.83 404
13.99 404
5-pregnene-3p,20p -di ol (P5-13p ) 16.46 489
5a-pregnane-3p,20p-diol -di oi 16.67 491
5a-pregnane-3p,20a-diol (pa -di ol) 17.08 491
NOTES:
OC retention times for MO/TBDMS derivatives (30m X .25mm i.d. SE -30 column)
Most prominent ionused for quantitation with selected ion mode
Doublet peaks are noted for 5a-DHP and 20a-SPTABLE 2: Systematic and abbreviated names. retention times and ionsmonitored on
GC/MS for each of the estrogens and an androgen.
Hormone Systematic Name (Abbreviated name) Retention Time (min) Ion Monitored
4-androstene-3,17-di one (AND) 8.95 344
3-hydroxy-1,3,5(10)-estratrien-17-one (E 1) 10.41 356
1,3,5( 10)-estratriene-3,170-diol (E2) 13.52 443
1,3,5(10)-estratriene-3,16a,170-triol ( E3) 22.40 367
NOTES:
BC retention times for MO/TBDMS derivatives (30m X .25mm i.d. SE-30 column)
Most prominent ionused for quantitetion with selected ion mode78
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FIGURE 4: Total ion chromatogram of progestin
standards on GC/MS full scan mode. Retention
time is on the horizontal axis and abundanceon
the vertical axis. Major peaks indicatedare:
doublet 5a -DHP (11.03 & 11.12 min), P4 (11.30
min), P5 (12.84 min), 3p -5P (12.98 min),doublet
20a -5P (13.83 & 13.99 min), P5-p p (16.49
min), p p -diol (16.67 min), & pa -diol (17.08
min). See Table 1 for full systematicnames.79
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FIGURE 5: Full scans of a) D4 -5a -DHP. b) 5a -DHP.
and c) P4. Major ions monitored are 347 for
D4-5a -DHP, 343 for 5a -DHP, and 372 for P4.
Both 5a -DHP and P4 are quantified against D4-
5e -DHP. Mass to charge ratio (m/z) is on the
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FIGURE 6: Full scans of a) D4 -P5 and b) P5. Major ions
monitored are 406 for D4-P5 and 402 for P5. P5 is
quantified against D4-P5. Mass to charge ratio (m/z)
is on the horizontal axis and intensity (abundance of
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FIGURE 7: Full scans of a) D4-3P -5P. b) 3p -5P. and c)
20a -5P. Major ions monitored are 408 for D4-311 -5P,
404 for-5P, and 404 for 20a -5P. Both 3p -5P
and 20a -5P are quantified against D4-3p -5P. Mass
to charge ratio (m/z) is on the horizontal axis and
intensity (abundance of ions) is on the vertical axis.
See Table 1 for full systematic names.a)
c)
Abundance Scan 617 (16.599 min):2101001.0
45
35000106
30000
25000
20000
15000
10000 133162 362
207
5000
0
4/Z->100 10 200 250 300 350 400 450 500
bundance
1 3
Scan 621 (16.640 min): 2101001.D
41
60000
50000
40000
30000
20000
159 359
283
10000 133 207
175
25787 331
0
/2->100 150 200 250 300 350 400 450
b)
d)
Abundance
1
scan
9
603 (16.454 minT: 2101001.D
60000
103
s000q
40000
489
30000
20000 281 357
10000 145
207
239 315
0
4/2->100 150 200 250 300 350 400 450
Abundance Scan 661(17.053 min): 2101001.D
80000 41
70000
60000
50000
40000
159
30000
20000 359
103
14
10000 207 283
15 533
0
100 150 200 250 300 350 400 450 500 4/2->
FIGURE 8: Full scans of a) DA-P p -diol, b) P5-0 p p p -diol, & d) p a -diol
Major ions monitored are 495 for D4-p p -diol, 489 forP5-p p,& 491 for
both p p -diol and p a -diol. All three diolsare quantified with D4-p p
diol. Mass to charge ratio (m/z) is on the horizontalaxis & intensity
(abundance of ions) is on the vertical axis. See Table 1for full names.b)
bundance
2000000
1500000
1000000-
500000
0
Inn ->
undanc
100000
80000
60000
40000
20000
8.95
10.41
91049
13 18
52
TIC: 0701006.0
22.4
10.00 12.00 14.00 16.00 18.00 20.00 22.00
107
137
3
Scan 489 (13.173 n1n): 0701006.D
207
382
413
0.1. ,44.k14
226268300325366
517,,
-> 100 150 200 250 300 350 400 450 500 550
83
FIGURE 9: a) Total ion chromatogram of estrogen and
androgen standards on GC/MS full scan mode and b)
full scan of 4-cholesten-3-one. In a) retention time
is on the horizontal axis and abundance on the
vertical axis. Major peaks indicated are: AND (8.95
min), El (10.41 min), E2 (13.52 min), &
E3 (22.40 min). The internal standard 4-cholesten-
3-one is shown at 13.18 min. In b) a full scan of 4-
cholesten-3-one is shown. The major ion monitored
is 413. Mass to charge ratio (m/z) is on the
horizontal axis and intensity (abundance of ions) is
on the vertical axis. See Table 2 for full
systematic names.a)
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See Table I & 2 for full systematic names.TABLE 3: Experiment 1 GC/MS assay performance
Plasma samples with D4-progestin internal standards extracted with Sep-Pak
Abbreviated Hormone Name
(see Table 1 for full names)
5a-DHP
P4
P5
313-5P
20a-5P
P5-1313
1313-diol
pa-diol
Z Recovery
( +/-SE)
Coefficient of Variation
I ntra assay % Inter assay %
98.2 (3.9) 8.9 11.6
93.2 (4.0) 9.4 11.7
97.1 (4.0) 9.1 12.4
97.7 (4.0) 9.2 12.5
81.7 (4.3) 11.8 19.8
99.5 (3.8) 8.5 13.0
97.2 (3.8) 8.7 13.7
91.7 (3.9) 9.4 13.5
NOTES:
Mean % recovery ( +I- standard error) of standards added to plasma, determined at 4 concentrations (25 to 200ng/m1) n=5 assays.
Coefficient of variation % (standards added to plasma at 4 concentrations over 9 assays).
00TABLE 4: Experiment 2 GC/MS assay performance
Plasma samples with 4-cholesten-3-one internal standard ether extracted
Abbreviated Hormone Name
(see Table 1 for full names)
5a-DHP
P4
P5
313-5P
20a-5P
P5-130
1313-dio1
Pot-diol
ZRecovery
(+/- SE)
Coefficient of Variation
I ntra assay % Inter assay %
84.2 (6.4) 15.3 18.3
87.7 (6.5) 14.7 23.3
87.1 (6.5) 14.8 18.1
106.4 (6.9) 12.9 16.9
115.2 (6.9) 11.9 21.4
109.9 (7.1) 12.9 20.5
108.0 (7.5) 13.9 19.1
99.2 (7.5) 15.1 20.8
NOTES:
Mean % recovery ( +/- standard error)of standards added to plasma, determined at 4 concentrations ( 25 to 200ng/m1) n=5 assays.
Coefficient of variation % (standards added to plasma at 4 concentrations over 5 assays).
00
00TABLE 5: Experiments 3 & 4 GC/MS assay performance
Medium samples with 4-cholesten-3-one internal standard extracted with Sep-Pak
Abbreviated Hormone Name
(see Table I for full names)
%Recovery
(+/- SE)
Coefficient of Variation
Intra assay % Inter assay %
5a-DHP
P4
P5
3(3-5P
20a-5P
P5-13f3
Pli-diol
Pa-diol
102.4 (3.8)
98.3 (3.8)
7.4
7.7
16.1
17.1
105.0 (4.0) 7.7 13.4
102.7 (4.1) 8.1 16.4
99.3 (4.2) 8.5 22.4
110.7 (4.3) 7.9 18.6
105.6 (4.2) 8.0 20.1
106.8 (4.2) 7.8 17.4
NOTES:
Mean % recovery ( +/- standard error)of standards added to medium, determined at 4 concentrations (25 to 200ng/m1) n=5 assays.
Coefficient of variation % (standards added to medium at 5 concentrations over 7 assays).
000TABLE 6: Experiment 4 GC/MS Assay Performance
Medium samples with 4-cholesten-3-one internal standard, extracted with Sep-Pak.
Abbreviated Hormone Name
(see Table 2 for full names)
X Recovery Coefficient of Variation
Infra assay % Inter assay %
AND 72.9 9.6 10.6
E1 86.4 7.9 8.6
E2 92.5 7.4 7.6
E3 109.9 4.0 4.1
NOTES:
Mean % recovery of standards added to medium, determined at 4 concentrations from 25 to 200ng/ml, n=2assays.
Coefficients of variation( standards added to medium at 4 concentrations over 2 assays).a)
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FIGURE 13: a) Total ion chromatogram & two full scans b)
P5 and c) 3p -5P from a fetal artery plasma sample.
In a) retention time is on the horizontal axis and
abundance on the vertical axis. The P5 peak is at 11.6
min and the 3p -5P peak is at 11.8 min. In b) & c)
mass to charge ratio (m/z) is on the horizontal axis
and intensity (abundance of ions) is on the vertical
axis. See Table 1 for full systematic names.92
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after D1-P5 infusion to the fetal artery. In a) both a
single-5P peak and doublet 20a -5P peaks have the
404 ion. In b) the corresponding D4- labelled 3p -5P
peak and doublet 20a -5P peaks with the 408 ion have
retention times slightly ahead of the unlabelled
compounds In a).In c) the single p a -diol peak is
shown with the 491 ion. In d) D4-p a -diol is shown
with the 495 ion. See Table 1 for full systematic
names.a)
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FIGURE 15: Full scans of incubation medium from a) Dar_
P4 in uterine endometrium. b) D4-P4 in placenta,
and c) D4-P51 pin fetal liver. Note the
differences in major ions compared to the
regular standards (see Figures 5c & 8b). Mass to
charge ratio (m/z) is on the horizontal axis and
intensity (abundance of ions) is on the vertical
axis. See Table 1 for full systematic names.a)
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FIGURE 17: Full scans of steroids in embryo incubation
medium a) P4. b) El.and c) E2. Note the major ions
are similar to regular standards (see Figures 5c &
10b,c). Mass to charge ratio (m/z) is on the
horizontal axis and intensity (abundance of ions)
is on the vertical axis. See Table 1 & 2 for full
systematic names.a) STD. CURVE FOR SDS PAGE
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FIGURE 18: a) Standard curve for SDS PAGE zymograph & b)
standard curve for eLH EIA. In a) LOG of molecular
weight (MW) of protein standards is on the horizontal
axis. Distance (cm) each protein migrated/total
distance is on the vertical axis. Unknown proteinmass
was calculated by solving "x" in the equation of the
line.In b) concentration of standards (ng/ml) is on
the horizontal axis and absorbance at 405nm is on the
vertical axis. Unknown concentrations were
determined by solving "x" in the equation of the line.
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FIGURE 19: Mean concentrations of Drogestins determined by
GC/MS for maternal vessels in the six pregnant mares
studied in Experiment 1. Figure a) is maternal artery
concentrations and figure b) is maternal vein levels.
Each progestin is indicated on the horizontal axis and
concentrations (ng/ml) are shown on the vertical axis.
Standard error bars are included. See Table 1 for full
systematic names.
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FIGURE 20: Mean concentrations of orogestins determined by.
GC/MS for fetal vessels in the six pregnant mares
studied in Experiment 1. Figure a) is fetal artery
concentrations and figure b) is fetal vein levels.
Each progestin is indicated on the horizontal axis and
concentrations (ng/ml) are shown on the vertical axis.
Standard error bars are included. See Table 1 for full
systematic names.99
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the P4 EIA at each concentration level. Each
progestin listed under the three actual
concentrations inhibited the binding of P4 to the P4
antibody by at least 50R. This was equivalent to 2.5
ng/ml of P4 in this competitive ER.
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FIGURE 2 1 : Mean concentrations of Drarogestinsover time
determined by GC/MS for maternal vessels in the two
pregnant mares studied in Experiment 2. Figure a) is
maternal artery concentrations & figure b) is maternal
vein levels. Each progestin is indicated in the legend.
See Table 1 for full systematic names. Concentrations
(ng /ml) are shown on the vertical axis and time in min
on the horizontal axis.101
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FIGURE 22: Mean concentrations of Drprogestins over time
determined by GC/MS for fetal vessels in the two
pregnant mares studied in Experiment 2. Figure a) is
fetal artery concentrations & figure b) is fetal vein
levels. Each progestin is indicated in the legend. See
Table 1 for full systematic names. Concentrations
(ng/ml) are shown on the vertical axis and time in min
on the horizontal axis.400
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FIGURE 24: Mean concentrationsof Drprogestins
determined by GC/MS for a) fatalovary & b) fetal
adrenal in Experiment 3. Eachprogestin is indicated
on the horizontal axis. See Table 1 for fullsystematic
names. Concentrations (ng/ml)are shown on the
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FIGURE 25: Mean concentrations of Drprogestins
determined by GC/MS for a) fetal liver & b) fetal
kidney in Experiment 3. Each progestin is indicated
on the horizontal axis. See Table 1 for full systematic
names. Concentrations (ng/ml) are shown on the
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FIGURE 26: Mean concentrations of 14-progestins
determined by GC/MS for a) placenta & b) uterine
endometrium in Experiment 3. Each progestin is
indicated on the horizontal axis. See Table 1 for full
systematic names. Concentrations (ng/ml)are shown
on the vertical axis.(n=2)
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FIGURE 27: Concentrations of brogestins determined by
GC/MS for a) an untreated embryo) b) an embryo
incubated with 2500 ng of D4 P5 in Experiment 4.
Each progestin is indicated on the horizontal axis.
See Table 1 for full systematic names. Concentrations
(ng/ml) are shown on the vertical axis.
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FIGURE 28: Concentrationsof Drogestins determined by
GC/MS for a) an embryo incubatedwith 5000 ng D4 -P5
& b) an embryo incubated with20000 ng of D4-P5 in
Experiment 4. Each progestin isIndicated on the
horizontal axis. See Table 1 forfull systematic
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FIGURE 29: Mean concentrations of estrogens and an androgen
determined by GC/MS for five embryos in Experiment 4.
Each hormone is indicated on the horizontal axis. See
Table 2 for full systematic names. Concentrations
(ng/ml) are shown on the vertical axis. Standard error
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FIGURE 30: SDS PAGE Zymographs of equine embryo medium
and tissue samples from Experiment 4. Lanes are
indicated across the top and molecular mass (Kilo-
daltons) of the protein bands are shown on the left of
the photograph. In a) lane 1is a medium blank, lanes 2
to 4 are medium samples, lanes 5 & 6 are embryo
tissue samples, lanes 7 & 8 are plasminogen activator
standards, and lane 9 has the protein standards.In b)
lane 1is a medium blank, lanes 2 & 3 are medium
samples, lanes 4 & 5 are embryo tissue samples, lanes
6 & 7 are plasminogen activator standards, and lane 8
has the protein standards.110
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FIGURE 31: SDS PAGE Zymograohs of equine embryo tissue
samples a) without amiloride & b) with
amiloride in Experiment 4. Lanes are indicated
across the top and molecular mass (Kilo-
daltons) of the protein bands are shown on the
left of the photograph. Lanes 1 and 2 have
plasminogen activator standards, and lanes 3 and
4 have embryo tissue samples.GU
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DISCUSSION AND CONCLUSIONS
The GC/MS techniques were effectivein determining steroid
content in both plasma and medium samples in this research.With
minor variations, from previously published techniques (Holtz) et al.,
1991), progestins and estrogens were identified and quantified with
definitivespecificity. Thefull-scansprovidedindisputable
identification of the hormones, while the selected ion mode enabled
quantification.
Itis the specificity that gives GC/MS techniques a distinct
advantage over immunoassays, as was determined in studies in the
1970's (Atkins et al., 1974 and 1976; Holtan et al., 1975a).The non-
specific binding of progesterone antisera to the various progestins
suspected in these immunoassay systems, was demonstrated with the
cross-reactivity studies using the commercial P4 EIA in Experiment 1.
Of the eight progestins, 5a-DHP, P5, 30-5P and 20a-5P, reacted
significantly at high concentrations (1000 ng/ml) in the P4 assay.At
100 ng/ml concentrations, 5a-DHP, P5 and 30-5P reacted in the P4
assay. Sincethesehormonesarenearsuchconcentrations
physiologically, this finding is significant.It is highly probable that
many immunoassay systems used today and in the past, react with other
hormones of similar structure.Cross-reactivity studies should be
included with results of immunoassays to prove their specificity for the
hormone analyzed.
In addition to specificity, GC/MS offers range, precision, and
accuracywhicharecomparableto,orsurpassthatofmost
immunoassays. However, even though GC/MS has proven to be a valuable114
toolinresearch foridentifyingandquantifyingthese numerous
progestins of similar structure, immunoassays still have their place in
the routine analysis of "progestin" profiles in diagnostic work. As more
knowledge is accumulated regarding the progestins of the pregnant
mare, specific antibodies for certain progestins will inevitably be
produced. Hamon et al. (1991) has already developed an El A system with
a specific antibody for 5a-DHP.
The use of deuterium labelled internal standards in the GC/MS
assay system, as was previously published (Ho ltan et al.,1991), was
used in the analysis of plasma samples in Experiment 1.In Experiments
2, 3 and 4, deuterium labelled precursor steroids (04-PS) were used in
the experimental procedures to confirm the identity of metabolic
products.This therefore necessitated the use of alternate internal
standards (4-cholesten-3-one) for quantificationofthe deuterium
labelledmetabolitesproduced. Thequantificationoftheeight
progestins was against one steroid (4-cholesten-3-one) rather than
four, as was the case with the deuterium labelled progestin internal
standards.This resulted in slightly greater assay coefficients of
variation for Experiments 2 through 4
Extraction efficiencies in the experiments varied depending on the
type of sample extracted (medium or plasma).Plasma extracted at
approximately the same efficiency with Sep-Pak and ether extraction
(about 70%).Medium samples however, extracted better (about 90%)
than plasma through Sep-Pak.However, since internal standards were
used in all samples, extraction efficiencies were not crucial.High
recoveries of the steroids were noted throughout the various assays.115
This recovery, or the ability of the assay to reliably report values
comparable to actual amounts added, is important to GC/MS analysis.
The use of radiolabelled precursors has been used extensively in
the study of equine hormones by Bhavnani et al. (1969,1971, and
1973a,b).Moss et al. (1979) also utilized radiolabelled steroids in
metabolic studies.Although their research provided data which
enhancedtheunderstandingofmetabolicpathways,theuseof
radioactive labels resulted in problems in the disposal of the animals
after the experiments. In equine tissue incubation studies, radiolabelled
steroids have also been used in the past (Ainsworth and Ryan, 1969;
Hamon et al., 1991). The use of radioactive labels in such studies does
provide a reliable method to trace metabolism, but does have the added
expense and precautions associated with the use of radioisotopes.
Deuterium labelling has been used in place of radiolabels in
metabolic studies.These non-ionizing isotopes reduced the health
threat to the research subjects.In addition, GC/MS can easily detect
thedifferenceofmassinanalyzingsampleswithdeuterium
metabolites. Bail lie et al. (1980) and Anderson et al. (1990) even used
deuterium labelled precursor steroids intravenously in pregnant women.
In Experiment 2, deuterium infusions (D4-P5) to fetal arterial vessels
provided a progestin metabolite label which was identified inthe
samples collected.The use of deuterium labelled precursor steroids
(D4-P5) has also proven to be a useful technique for tissue (Hamon et al.,
1991;and Experiment 3)and embryo (Experiment4)incubation
metabolic studies.
The GC/MS and associated techniques were applied in Experiments
1through 4.In Experiment1,the identity and concentration of116
progestins in fetal and maternal vessels of late gestation mares were
confirmed and found to compare favorably with the only previously
published study of this kind (Holtan et al., 1991). Experiments 2 and 3,
again utilizing GC/MS, provided new and important information on the
metabolism of progestins during pregnancy.In Experiment 2, primary
metabolites were determined for the maternal circulation (20a-5P) and
fetal circulation (30-5P).Experiment 3 indicated specific sites of
metabolism for some progestins (placenta produced P4, placenta and
endometrium produced 5a-DHP, fetal tissues produced 30-5P, fetel liver
produced P5-13I3,and endometrium produced 13a-diol).The GC/MS
identification of the steroids (progestins, estrogens, and an androgen) in
the early equine embryos in Experiment 4, has not been documented in
the literature previously.In the embryo work, plasminogen activator
was identified and characterized whichisalso new information.
Experiment 5 provided evidence that at least two of the progestins
found in pregnant mares (5a-DHP and 3I3-5P) are not as physiologically
active as P4 at comparable concentrations in the cyclic mare.The
biological actions of the progestins (excluding P4) have not been
investigated previously in horses.
In Experiment 1, all six mares appeared to have similar levels of
each individual progestin, with the exception of the earlier gestation
(160 d) mare having higher P4 levels (P < .05) indicating that the corpus
luteum was still contributing P4.The two mares at 313 d had higher
20a-5P levels (P < .05), which was due to advanced gestational age.In
previous work (Holtan et al., 1991), a rapid increase in progestins during
the last 30 d pre-partum was observed.117
Tremendous variations (P < .05) were noted between the four
vessels for the eight hormones.It was noted that P4 was highest (P <
.05) in the fetal vein (15.5 ng/ml), with the fetal artery lower (7.8
ng/ml), and negligible amounts in the maternal circulation. This finding
is consistent with the early work published by Short (1959) which
indicated P4 was found only in the placenta and umbilical cord blood.
Holtan etal.(1991) also found similar concentrations of P4 in
cannulations of the fetal vessels.The explanation for the differential
from fetal vein to artery is evident from tissue incubation studies.
Hamon et al. (1991) noted that placental tissue was capable of the
metabolism of P5 to P4, with low conversion of P4 to 5a-DHP, but found
mare endometrium produced significant amounts of 5a-DHP from P4.
Ainsworth and Ryan (1969), also using tissue incubations, found P5 and
P4 were metabolized by the placenta, with some P4 converted to 5a-
DHP, 30-5P, 20a-5P and pa-Diol.Therefore, the concentration of P4
would increase fromfetalarterytofetalvein,and sincethe
endometrium metabolizes P4 to other metabolites, P4 is unlikely to
appear in maternal vessels.
The predominant fetal vein progestin in Experiment 1was 5a-
DHP at 216.4 ng/ml.Holtan et al. (1991) also noted that 5a-DHP was
highest in the fetal vein.Previous studies help explain this finding.
With radiolabelled infusions, Moss et al. (1979) determined that P4 was
converted to 5a-DHP in the placenta. This was also noted in Ainsworth
and Ryan's work (1969).However, Hamon et al. (1991) indicated the
endometrium produces 5a-DHP, which may pass back to the fetus.
The fetus is the probable source of P5 (630.8 ng/ml) since it is
the predominant (P<.05) steroid in the fetal artery as notedin118
Experiment 1, and previously by Ho ltan et al. (1991). This P5 from the
fetus (via the fetal artery) is converted to P4 in the placenta, which is
subsequentlyeithermetabolizedfurtherbytheplacentaand
endometrium (and therefore P4 is not seen in the uterine vein or
maternal artery circulation), or passed to the fetus (via the fetal vein)
where it is converted to other metabolites.
The fetal artery also had the highest (P < .05) levels of 33 -5P
(117.9 ng/ml), P5-p3 (131.4 ng/ml) and 130-diol (32.3 ng/ml).The
uterine vein had the highest (P < .05) levels of 20a-5P (767.6 ng/ml) and
0a-diol (202.2 ng/ml). These relative relationships were also noted by
Holtan et al. (1991).From these differences in levels it could be
proposed that 30- and 200-hydroxylations occur on the fetal system,
while 20a-hydroxylations occur on the maternal side.Holtan et al.
(1991) noted a 50% decrease in concentration of 20a-5P from the
uterine vein to the maternal artery, and therefore speculated that the
endometrium produced 20a-5P.The maternal vessel concentration
differences of 20a-5P noted in Experiment 1 (767.6 ng/ml in the uterine
vein and 533.3 ng/ml in the maternal artery), also indicate that the
endometrium produces 20a-5P.
With the infusions of D4-P5 to the fetal artery (Experiment 2), it
was noted that the major metabolism of P5 seemed to occur within the
first 10 min after infusion.After 10 min, levels of all D4-progestins
declined in all vessels except in the fetal vein which decreased after
the 60 min sampling. There were no samplings between 10 and 60 min
analyzed from the fetal vessels since low sample volumes were
collected to avoid hemorrhagic insult to the fetus.Subsequently,
pooling of fetal samples was necessary to attain sufficient volumes for119
GC/MS analysis.Therefore, the fetal vein decrease probably occurred
just after 10 min.Since larger volumes were collected from the
maternal vessels, without risking a serious decrease in blood volume,
there were several samples of sufficient volume for analysis between
10 and 60 min.Additionally, it appears that an approximate 10-fold
decrease in magnitude of the progestins occurred from the fetal artery
to vein, indicating that the amount of D4-P5 may not have been adequate
to supply precursors for both maternal and fetal systems. The maternal
system was at levels comparable to fetal artery concentrations. These
findings will be helpful in the design of future protocols. More frequent,
earlier samplings and increased concentration of infused precursor may
help to determine progestin metabolism completely.
The results from Experiment 2 did indicate some of the major
metabolites in the fetal and maternal systems.Deuterium labelled
progestins varied between vessels and over time (P < .05), due to D4 -313-
5P, D4-P4 and D4-5a-DHP being greater in magnitude in the fetal
vessels, and D4-20a-5P and D4ia-diol predominating in the maternal
circulation. The maternal artery had lower levels (P < .05) of the two
predominant maternal D4-progestins than the uterine vein.This
supports the idea proposed by Ho ltan et al. (1991) that the 20a-
hydroxylations do indeed occur in the maternal system.
However, the situation remains somewhat unclear regarding the
fetal side of the metabolic scheme. The higher D4 -3p -5P in the fetal
artery indicates 3(3-hydroxylation in the fetus. Since very low levels of
the remaining hormones were detected, it is possible that either in the
10 min sampling, only the last portion of the metabolism of the D4-P5
was detected, or that the level infused was not physiologically high120
enough to accurately trace metabolism completely, at least on the fetal
side.It is highly probable that the metabolism is indeed very rapid in
the placenta and endometrium since only low levels of D4-P4 and D4-5a-
DHP were detected compared to other metabolites.This may indicate
that they were merely transient metabolic intermediates since high
levels of D4-313-5P were found in the fetal vessels, and high levels of
D4-20a-5P were seen in the mare's circulation.However, very low
levels of the 200-hydroxylated compounds (P5-130 and 1313-dion were
noted in the fetal circulation, which may indicate that there were not
enough precursor progestins available to form these metabolites in their
usual magnitudes.The important findings of Experiment 2 were
however, that the major metabolite of the mare is 20a-5P, while the
major metabolite produced by the fetus is 3I3-5P.
In Experiment 3, enzymatic capabilities of tissues suspected to
be involved with the production ofthe various progestins were
evaluated.Although all the tissues tested produced D4-P4,placental
tissue produced the most (P < .05). This agrees favorably with previous
work (Short, 1959; Ainsworth and Ryan, 1969; Hamon et al., 1991). In a
histochemical study (Flood and Marrable, 1975),it was noted that
hydroxysteroid dehydrogenase enzymes are located in placental and
uterine structures in all stages of pregnancy.This is the enzyme
required for the conversion of P5 to P4.
The major sources (P < .05) of D4-5a-DHP included the placenta,
uterine endometrium and fetal ovary.These findings are consistent
with the levels observed in the vessel cannulations of Experiment 1, and
by Holtan et al. (1991), as well as tissue studies of Hamon et al. (1991).121
The highest (P < .05) production of D4-30-5P occurred in the fetal
ovary, adrenal, liver, and mare endometrial tissues. This production of
D4-30-5P in the fetal tissues is in agreement with the model suggested
previously regarding 313-hydroxylations in the fetus (Ho ltan et al., 1991).
Although uterine endometrial tissues produced some D4-3I3-5P, D4 -P5-
pp and D4-013-diol in vitro, in the intact system with other precursors
present, alternate enzyme systems may be activated.Several tissues
(uterine endometrium, fetal ovaries, adrenals and liver) produced D4-
20a-5P, but none were significantly higher than the others.Itis
possible that since this metabolite is suspected to be metabolized in
the mare's endometrium, in vivo other metabolites may be available for
its production. The uterine endometrium produced more D4-0a-diol than
the other tissues which supports the idea that 20a-hydroxylation occurs
on the maternal side. A significant (P < .05) amount of D4-P5-1313 was
produced by the fetal liver compared to other tissues. This fetal source
may be activated in distressed foals since they produce elevated levels
of this hormone and other 200-hydroxylated compounds (Houghton et al.,
1991; Rossdale et al., 1992).
It must be taken into consideration when analyzing data from
tissue incubations that only single, isolated systems are examined and
different metabolites may predominate in vivaVarious additional
precursors and feedback systems are present in the whole system. The
impact of feedback of the progestins was examined and found to be
significant in human studies (Powell and Challis, 1986; and Powell et
al., 1986).122
However, Experiment 3 provided a more extensive analysis of
progestin metabolisminfeto-placentaltissuesthananyresults
published previously. The primary conclusions from this study indicate
that the placenta and endometrium metabolize P5 to P4 and 5a-DHP. The
fetal liver is the location of the production ofP5-1313, which is a
hormone elevated by fetal stress.Additionally, fetal tissues produced
3 (3 -5P.
Cummulatively, these first three Experiments would Imply a
complicated systemofmetabolisminthelate-gestationmare.
Additional studies such as these will be necessary to completely
determine the entire metabolic scheme.However, at this time with
these studies and previous work, it would appear that the fetus is the
primary source of P5,This P5 is transported to the placenta and
endometrium where it is enzymatically altered to form P4 and 5a-DHP.
The 5a-DHP and P4 are transported to the fetus where 3(3 and 200-
hydroxylations occur to form 30-5P and (30-diolin the fetal liver,
adrenals and gonads.Some of the P5 is also hydroxylated (probably
mostly in the fetal liver) to form P5-00.The 5a-DHP formed in the
mare's uterus is probably the primary precursor for the 20a-5P and fki
diol found in the maternal vessels. Some 5a-DHP obviously crosses back
to the fetal vein due to the high levels detected in this vessel. A steroid
metabolic flow diagram (Figure 34) and a diagram of the feto-placental
unit with progestin sources indicated (Figure 35) help to visualize this
metabolic model.
It is unknown why the pregnant equine produces this wide variety
of progestin compounds. Research regarding the biological activity of
these substances, with the exception ofP4, has receivedlittle123
attention. The feedback inhibition of the gonadotropins by P4 has been
known for years, and has been extensively examined in mares (see
Literature Review for details). However, no studies have been published
analyzing biological activity of any other progestins in pregnant or
cycling equines.
In Experiment 5, the biological activity of two of the progestins
(5a-DHP and 313-5P) were tested in non-pregnant, cyclic mares and
compared to P4. At the same treatment levels, it was determined that
neither 5a-DHP nor 313-5P consistently block estrus and ovulation.By
contrast, P4 treated control mares showed the expected prolonged
diestrus and delayed ovulation until after treatment was withdrawn.It
was also noted that the mares treated with these two reduced
progestins,orPFG2aalone,showedsomewhatelevatedeLH
concentrations compared to the P4 treated and the untreated control
mares. Therefore, it seems that the negative feedback exerted to inhibit
eLH release from the pituitary by P4 treated mares, and by endogenous
P4 in the untreated control mares, was not elicited by 5a-DHP, 313-5P,
or in mares treated with only PGF2a.
From the studies in pregnant mares, it was noted that the reduced
progestins are present at levels much higher than P4. Therefore, it may
be that the levels of treatment in Experiment 5 were inadequate to
demonstrate the actual physiological activity of these progestins. Work
with cyclic rats (Sridharan et al.,1974) has indicated that larger
amounts of P5 and 5a-DHP were necessary to elicit the same response
as P4, and that 3a-5P was ineffective at any dosage level. Others have
reported differential effectiveness of the progestins on inhibition of LH124
in rats (Zanisi and Martinin, 1974; Nuti and Karavolas, 1977).Similar
situations may exist in the equine.
The work in Experiment 4 examined the metabolism of the
progestins from D4-P5, as well as the determining the content of
progestins and estrogens in the early equine embryo.Previous work
(Marsan et al., 1987) indicated different cell types are responsible for
the production of progesterone and estrogen.Several studies (see
Literature Review for details) have indicated the presence of estrogens
in the early embryo.The intermediate metabolites between the
progestins and estrogens have never been addressed. Additionally, in the
previous studies, non-specific RIA systems were used, consequently
definite identifications of the hormones were not possible.With full-
scan GC/MS, positive identifications of the estrogens and progestins
were attained.
The results from the incubations of 14 d to 18 d embryos indicate
that the metabolic capability is present for the production of the eight
progestins which have been identified in late-gestation mares.All
seven D4-progestins derived from D4-P5 were present in the incubation
medium, with D4-P4 being the predominant product. When the amount of
D4-P5 was increased, there was an increase in D4-P4 produced.Large
amounts of E2 were noted in the embryo medium as well as E3, El and
AND. Since the embryos studied in this experiment were near the time
of maternal recognition of pregnancy, it is probable that these steroids,
in particular P4 and the estrogens, are involved with this mechanism.
Therefore, steroid production by the embryo may be important to
pregnancy maintenance in the early stages of gestation.125
Theidentification and characterizationoftheplasminogen
activator in the equine embryo has not been documented previously. The
plasminogen activator appears to be primarily a 50 to 55 KD urokinase
type, since it was inhibited by amiloride.This information indicates
that the major plasminogen activator present in equine embryos is
similar to that found in bovine embryos (Coates and Menino, 1991) and
ovine embryos (Bartlett and Menino, 1991).In addition, however, there
appears to be some tissue type plasminogen activator of about 70 to 75
KD.Inhibitor complexed to both types of plasminogen activator are
suspected to have resulted in the two additional bands at approximately
88 and 95 KD.
Thebiologicalfunctionoftheplasminogenactivatoris
speculative at this time in the equine as well as the other species. A
number of ideas are discussed in the Literature Review section.Its
presence in the equine embryos at this early stage may indicate a role in
tissue reorganization.Since it is suspected that there are inhibitors
present also, the peak activity of this enzyme may actually occur at
some other time, such as at the time of placentation.The progestins
and estrogens also found to be present in these embryos, may be
involved with the expression of plasminogen activator as was noted by
Mullins et al. (1980) and Fazleabas et al. (1983).126
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FIGURE 34: Steroid metabolic flow diagram. See Table 1 and 2
for full systematic names. See Figures 1, 2 and 3 for
structures. Beginning with P5, the progestin
metabolites are shown on the left side of the diagram.
The androgen and estrogens found in the embryo work are
shown on the right side of the diagram.127
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indicated. See Table 1 for full systematic names.
P5 from the fetus (via fetal artery) is metabolized to P4
and 5a -DHP in the placenta and uterus. Some 5a -DHP
goes to the fetus (via fetal vein) and is hydroxylated to
3p -5P and a p -diol (both high in fetal artery). The
5a -DHP in the uterus forms 20a -5P and p a -diol (both
high in maternal vessels). Some P5 is hydroxylated in
the fetal liver to P5-a p (high in fetal artery).128
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